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CHAPTER 1
INTRODUCTION
From time in memorial, humans have tried to make sense of their environment and
develop new tools to conquer the ever-increasing challenges they face in life every day. Human
disease is no exception; the advances in science have propelled the development of tools and
medicines to fight many deadly diseases. However, seemingly harmless but dangerous microorganisms continue to plague and torment the human race in a non-relenting fashion. The
antibiotic revolution began after the accidental discovery of penicillin by Alexander Fleming in
1928.1 Since then, new and better antibiotics have been developed, but the increasing use and
misuse of existing antibiotics in humans and agriculture has resulted in bacteria that are highly
resistant to current antibiotics (superbugs). Nowadays, over 70% of bacterial infections in the
hospitals are resistant to at least one of the drugs most commonly used to treat them.2 This has
resulted in increased mortality rate and longer hospital stays, placing a huge economic burden
on patients and the government.2 The total cost of antimicrobial resistance in the U.S.A. is
approximately $30 billion annually.2 Development of new and effective antibiotics is therefore a
high priority for the healthcare industry. The long-term goal of this project is to develop new
and effective antibiotics. Before going into the details of the project, it is worthwhile discussing
current antibiotics, their mechanism of action against bacteria, and how bacteria develop
resistance.
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1.1

Mechanism of Action of Current Antibiotics
A variety of antibiotics target different parts of the bacterium cell. They can be grouped

into three major classes, depending on their site of action. There are antibiotics that kill
bacteria by inhibiting cell wall synthesis, nucleic acid metabolism, or protein synthesis.
First of all, antibiotics such as penicillins, cephalosporins, carbapenems, and
monobactams target the cell wall of bacteria. This group of antibiotics is collectively known as
the β-lactams.3 In actively dividing bacteria, β-lactams inhibit the enzymes needed for the
proper synthesis of the bacterial cell wall. Inhibition of these enzymes subsequently activates
the autolytic system of the cell, leading to lysis and cell death.4
Furthermore, fluoroquinolones (examples: norfloxacin and ciprofloxacin) inhibit
bacterium cell growth by interacting with DNA gyrase and DNA topoisomerase IV.5 DNA gyrase
is responsible for relieving torsional stress that accumulates ahead of the replication fork by
introducing negative supercoils. DNA topoisomerase IV aids this process by introducing nicks at
the appropriate DNA sites. Interaction of fluoroquinolones with these two enzymes inhibits
DNA replication, and accumulation of nicked DNA triggers pathways that eventually lead to cell
death.5
The last class of antibiotics inhibits protein synthesis in bacteria. Protein synthesis is an
essential process for all living organisms; hence, a wide variety of antibiotics target the protein
synthesis machinery of bacteria. Among these antibiotics are tetracyclines, chloramphenicol,
and aminoglycosides, just to mention a few.6-8 The mechanism by which these antibiotics inhibit
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protein synthesis will be discussed in detail in the next section. The different antibiotics, their
target sites, and mechanism of resistance are summarized in Table 1.1.
Table 1.1: Bacterial antibiotic targets and resistance mechanisms associated with different
antimicrobial agents.
Target
Antimicrobial Agent
Cell wall synthesis β-Lactams
Glycopeptides
Aminoglycosides
Macrolides
Linsosamides
Ketolides
Sterptogramins
Tetracyclines
Chloramphenicol
Oxazolidinones
RNA synthesis
Rifamycin
DNA synthesis
Coumarins
Naphthyridines
Quinolones
2-Pyridones
Intermediary
Sulfonamides
metabolism
Trimethoprim

Resistance Mechanism
AM, TM, EF, RMP
TM
AM, TM, EF, RMP
TM, AM, EF
TM, AM, EF
TM, AM, EF
TM, AM, EF
TM, EF
AM, TM, EF, RMP
TM
TM
TM, EF, RMP
TM, EF, RMP
TM, EF, RMP
TM, EF, RMP
TM

Reference
9
10
11-14
15-16
15-16
15-16
15-16
17
18
19
20
21-22
22
22
22
23

TM: target modification, AM: antibiotic modification, EF: efflux, RMP: reduced membrane
permeability.

1.2

Antibiotic Resistance
In spite of the availability of diverse antibiotics, antibiotic resistance against all the

different classes of antibiotic has compromised their effectiveness. Antibiotic resistance
mechanisms include target modification; the antibiotic target is modified by mutation or
methylation so that the antibiotic is no longer able to effectively bind to it.9-10 This kind of
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resistance mechanism is seen in all the major classes of antibiotics. Resistance can also occur
when membrane proteins are modified, resulting in reduced uptake of the antibiotic.11-12
Conversely, over-expression of efflux pumps in the membrane could result in reduced
accumulation of the antibiotic in the cell, thereby reducing its effectiveness.14 Antibiotics can
also be rendered ineffective by enzymatic modifications or hydrolysis. There are enzymes that
catalyze the addition of certain functional groups to the antibiotic, thereby rendering it
inefficient in binding to its target.15-16 Refer to Table 1.1 for a summary of the different
resistance mechanisms and the antibiotics that they affect.
All of the antibiotic resistance mechanisms described above are different strategies that
antibiotic-producing bacteria use to protect themselves from the antibiotics that they produce.
It is probable that current antibiotic resistant pathogens derived these antibiotic-resistance
determinants through gene transfer.24-25 Gene exchange occurs in the soil or the
gastrointestinal tract of humans and animals where selection pressure of antibiotics is heaviest.
Bacteria can exchange genetic information through transformation, phage-mediated
transduction, conjugation, or transposition. These processes can spread antibiotic resistance
determinants among bacteria.24-26
The antibiotic resistance problem is now at the highest peak and there is a dire need to
develop new and effective antibiotics. Many researchers have taken up this challenging task.
My thesis work focused on developing new aminoglycoside antibiotics that inhibit protein
synthesis. Therefore, the next section will focus on structure and function of the protein
synthesis machinery of the cell, the ribosome.
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1.3

The Ribosome

1.3.1 Ribosome Structure
The bacterial ribosome is the protein synthesis machinery of the cell. It is composed of
two subunits, the 50 S subunit, which is made up of 23 S rRNA, 5 S rRNA, and 34 proteins (L1L31 there are 4 copies of L12) and the 30 S subunit, which is composed of 16 S rRNA and 21
proteins (S1-S21)27. “L” and “S” in the nomenclature of the ribosomal proteins refer to the large
and small subunit, respectively. The “S” in the nomenclature of the ribosomal subunit (for
example, 50 S) is a measuring unit known as the Svedberg unit, which is a measure of the rate
of sedimentation of a component upon centrifugation. A summary of the components of the E.
coli ribosome is shown in Table 1.2.

Table 1.2: RNA components of the bacterial ribosome (E. coli) 27-32
Type of
RNA
16 S
5S
23 S

Approximate number
of nucleotides
1,541
120
2,904

subunit
Location
30 S
50 S
50 S

Proteins present in
subunit
S1-S21
L1-L34
L1-L34

The secondary structure of the ribosome is formed as a result of the specific base
pairing of the different parts of the RNA molecule.33 The secondary structure of the 16 S rRNA
(Figure 1.1)34 is divided into three major domains; the 5′ domain, the central domain, and the 3′
major domain, and a fourth domain called the 3′ minor domain. There are 45 helices in the 16 S
r RNA, which are named with a lower case “h” followed by the helix number (for example, h31).

6

The 23 S rRNA on the other hand is made up of 6 domains (I to IV) (Figure 1.2).35 The domains
consist of over a hundred helices, which are named with an upper case “H” followed by the
helix number (for example H69). Unlike DNA that exists as a double strand, single strands of
RNA can fold into more complex patterns resulting from unpaired nucleotides and mismatches
that form bulges, loops and junctions.36 These structural elements allow the RNA to adopt
complex three-dimensional structures. Even more complexity is achieved upon binding of
ribosomal proteins.37 Typically ribosomal proteins have one or more globular domains with long
N- or C- terminal domain extensions that penetrate to fill the gaps in the rRNA (Figure 1.3).38
The ribosomal proteins are post-translationally modified by methylation (S11, L3, L7/L12, L11,
L16, and L33), acetylation (S5, S18, and L12), glutamic acid residues (S6), and an isoaspartate
residue (S11).39-42 Furthermore, all the ribosomal proteins lack sequence homology with the
exception of L12 and L7, which have identical amino acid sequences with the exception of an
acetyl group. L12 is converted to L7 when acetylated.39 The abundance of these posttranslational modifications in the ribosomal proteins suggests that they may play a significant
role in fine tuning the ribosome structure and or function.38

1.3.2 Ribosome Assembly/Biogenesis
The 16 S, 23 S, and the 5 S rRNAs are transcribed as a single primary transcript from one
of the rrn operons.43-44 The new transcript starts to fold during transcription into local
secondary structures. Simultaneously, ribosomal modifications and binding of some ribosomal
proteins occur.
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Figure 1.1: The secondary structure of E. coli 16 S rRNA shows the different helix numbers in
blue color and the different domains; 5′ domain (5′), 3′ major domain (3′M), 3′ minor domain
(3′m) and the central domain (C).34, 45
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Figure 1.2: The secondary structure of E. coli 23 S and rRNA is shown. The different domains are
numbered I-VI.35, 45

The 16 S RNA is modified at 11 positions, ten of which are methylations and one is
pseudouridine.46-47 The 23 S on the other hand is modified at 25 positions with 14 methylations,
nine pseudouridines and one unknown modification.46-47 Binding of ribosomal proteins to the
rRNA happens in a hierarchical and cooperative manner in which early binding proteins arrange
the binding sites for late-binding proteins.48 In general, ribosomal proteins S4-S9, S11-S13, and
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S15-S20 assemble first, and after undergoing conformational changes, proteins S2,S3, S10-S14,
and S21 bind to form the 30 S particle.48

Figure 1.3: Structure of the bacterial ribosome is shown. This figure was generated with PyMol
software49 using coordinates from PDB file 2WDG.50

Assembly of the 50 S particle is much more complex and requires metal ions such as
Mg2+ to help stabilize the RNA structure.32 Herold and Nierhaus presented a detailed assembly
map of the 50 S subunit in 1987,32 which has since been updated by Williamson.51 The primary
transcript is further processed by RNases to generate mature 30 S and 50 S rRNAs. The whole
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process of maturation and assembly of ribosomal subunits takes approximately 2 minutes at 37
°C.52
There is an abundance of complementary sequences present in the rRNA;28, 31 therefore,
there is a high probability for mis-folding of the rRNA. RNA chaperones, helicases, and GTPases
help manage RNA folding.53 These proteins in addition to maturation factors help lower the
activation energy required for maturation and also rescue kinetically trapped intermediates or
mis-folded RNAs to their native state.32, 53-54 Mature ribosomes are now ready and available for
protein synthesis.

1.4

Ribosome Function

1.4.1 Protein Synthesis
Protein synthesis or translation is a process by which a sequence of codons on an mRNA
is used as a template for polypeptide synthesis by the ribosome.55 The 70 S ribosome has three
tRNA binding sites on each of its subunits (30 S and 50 S) known as the aminoacyl (A), peptidyl
(P) and the exit (E) sites (Figure 1.3).56 The initiation of protein synthesis is promoted by
initiation factors IF1, IF2, and IF3. At the onset of translation, IF3 binds to the 30 S subunit and
promotes dissociation of the 70 S into the 50 S and 30 S subunits. Binding of IF3 to the 30 S
prevents re-association of 30 S with the 50 S subunit. It also helps in the selection of the
initiator tRNA (fMet-tRNAfMet ) by destabilizing the binding of other tRNAs to the P site.57 IF1
also binds to the base of the A site and directs the initiator tRNA to the P site by blocking the A
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site.58 Next, IF2, mRNA, and fMet-tRNAfMet are recruited to the 30 S subunit in an unknown
order. The anti-Shine-Delgarno (antiSD) sequence at the 3′ end of the 16 S rRNA interacts with
its complementary sequence (typically GGAGG) on the 5′ untranslated region (5′ UTR) of the
mRNA.59 This positions the initiation codon in the P site of the ribosome. Current data suggests
that the Shine-Delgarno is not the sole determinant for identification of the start codon.
However, more importantly, the mRNA folds in a specific manner making the start codon
uniquely available for interaction with the 30 S subunit.60-62 This idea is supported by evidence
from other groups who demonstrated that initiation of protein synthesis is possible without an
SD-antiSD interaction.62-63 Furthermore, there have been reports of translation of leaderless
mRNAs64 and translation of prokaryotic mRNAs with translation initiation regions similar to
eukaryotic ribosome entry sites65, which do not involve SD-antiSD interactions for translation
initiation to occur.
After the mRNA docks at the P site of the 30 S ribosome, the anti-codon of the initiator
tRNA interacts with the start codon (usually AUG, GUG or UUG). This complex constitutes the
30 S initiation complex.66 Next, IF1 and IF3 are ejected and the 50 S subunit associates with the
30 S subunit with subsequent hydrolysis of GTP to GDP, which leads to the release of IF2. The
fMet-tRNAfMet -bound 70 S initiation complex is now ready for elongation. One critical step in
the initiation process is the accuracy of selection of the initiator tRNA. This process is promoted
by IF2, which interacts directly with the initiator tRNA on the ribosome and IF3, which acts has a
proof-reading capability by destabilizing non-cognate tRNAs (Figure 1.4).67
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Figure 1.4: A schematic diagram depicts the process of translation initiation through to peptidebond formation in a bacterial system. Refer to the text for a detailed description of the process.
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The elongation process involves repetitive cycles of aminoacyl-tRNA (aa-tRNA) selection,
peptide-bond formation, and mRNA-tRNA translocation. This process takes place at an
estimated rate of about 15-20 amino acids per second, with an error rate less than 10-4.68 This
amazing fidelity is achieved by concerted efforts of elongation factor Tu (EF-Tu), elongation
factor G (EF-G), and a series of ribosomal conformational changes discussed below. The
elongation process begins with the delivery of the aa-tRNA to the fMet-tRNAfMet -bound 70 S
initiation complex in the form of a ternary complex consisting of aa-tRNA bound to EF-Tu and
GTP.69-70 Correct anti-codon–codon interaction triggers the hydrolysis of GTP, which causes the
dissociation of EF-Tu.71-72 The 3′ acceptor arm of the tRNA is accommodated into the P site of
the 50 S and peptide-bond formation occurs.73 Selectivity of this process is achieved by a
double-checking mechanism, consisting of the initial selection and a proof-reading step. During
the initial selection process, aa-tRNA reversibly interacts with the 30 S decoding region for
initial codon recognition.74 Conformational changes occur in the aa-tRNA (described as a
molecular spring model) such that only the correct aa-tRNA can sufficiently be stabilized in the
decoding center.72, 75 The interaction between the cognate tRNA and the ribosome induces
conformational changes in the 30 S subunit; specifically, nucleotides A1492 and A1493 flip out
of the internal loop of helix 44 and nucleotide G530 changes conformation from syn to anti to
interact with the sugar edge of the cognate tRNA.75-76 This favorable interaction triggers the
GTPase activity of EF-Tu. During the proof-reading step, GTP is hydrolyzed, and the release of
inorganic phosphate induces conformational changes in EF-Tu leading to its dissociation from
the ribosome.77 At this point, any near-cognate tRNA that may have survived the initial

14

selection process is likely to dissociate from the ribosome due to unfavorable interactions
between partial mismatch interaction between the tRNA and the decoding center.75 Next, the
3′ CCA of the tRNA is positioned at the P site of the 50 S subunit, which catalyzes peptide-bond
formation between the α−amino group of the incoming amino acid and the carboxyl group of
the amino acid attached the P-site tRNA (Figure 1.4).73
After peptide-bond formation, translocation occurs. This process involves the
movement of the mRNA-tRNA complex from the A and P sites to the P and E sites, respectively.
This process requires GTP hydrolysis from elongation factor G (EF-G). The binding of EF-G to the
ribosome triggers a ratchet motion in which there is a counterclockwise movement of the small
subunit with respect to the large subunit, 78-79 this movement shifts the mRNA bound tRNA to
the P/E hybrid state. Next there is hydrolysis of GTP, and a reversal motion occurs where the
small subunit moves back to its original position.80 This movement shifts the mRNA up by one
codon, which leaves the A site vacant and ready for another aa-tRNA to bind and repeat the
cycle of protein synthesis. The description of the translocation process given above was refined
by major contributions made in the past decade by Joachim Frank and co-workers among
others (Figure 1.5).78-80
The process of decoding and translocation continues until a stop codon (UAA, UAG or
UGA) docks in the A site of the ribosome. This step leads to recruitment of release factors RF1,
RF2 and RF3 to the ribosome, and triggers the release of the polypeptide chain from the P
site.81 After the release of the polypeptide, GTP binds to RF3, resulting in a conformational
change in RF3, which leads to the dissociation of RF1 and RF2.82
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Figure 1.5: A schematic diagram depicts the process of translocation through to ribosome
recycling in a bacterial system. Refer to the text for a detailed description of the process.
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Upon GTP hydrolysis, RF3 also dissociates from the ribosome leaving the mRNA and deacylated
tRNA in the P site of the ribosome. The ribosome is recycled with the help of the ribosome
recycling factor (RRF) and EF-G. The binding of these two factors to the ribosome and
subsequent hydrolysis of GTP leads to the dissociation of the 70 S ribosome from the mRNA and
tRNA (Figure 1.5).83

1.4.2 A Closer Look at the Decoding Region of the Ribosome
The decoding region is one of the most important parts of the ribosome that ensures
the correct synthesis of proteins by accurately decoding the message embedded in the mRNA.
Different conformational changes occur in the decoding region (especially helix 44 (Figure
1.6A)) to aid this process.84 One such conformational change is the flipping out of A1492 and
A1493, which has been well characterized by different biochemical and biophysical
approaches.85-87 The highly dynamic nature of the decoding region has made it a target of many
antibiotics. Many antibiotics such as aminoglycosides bind to the decoding region and induce
structural changes that compromise the fidelity or abort the synthesis of the polypeptide.88-89
To simplify the study of the decoding region, Purohit and Stern were able to show that a 50nucleotide model of the decoding region (Figure 1.6B) is able to fold into the right
conformation and bind to antibiotics with affinities similar to that observed in the context of
the whole ribosome.90 This work opened the door to new experiments geared toward
understanding the function of the decoding region. Since then, it has also been shown that
even shorter RNA constructs representing the A site are able to bind to antibiotics effectively
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(Figure 1.6C).89, 91 This work has facilitated the understanding and design of antibiotics to target
the A site of the ribosome. Various A-site RNA analogues from different species and analogues
representing different mutants can be easily studied by using shorter A-site RNA model
representations. 92

A)

B)

C)

Figure 1.6: Reduction of the decoding region into shorter RNA models is depicted: a) the
structure of the ribosomal 30 S subunit with the decoding region (helix 44) highlighted in red
the figure was generated with PyMol using coordinates from PDB file 3I8G; b) the 50-nucleotide
model of the decoding region introduced by Purohit and Stern;90 c) the 27-nucleotide model of
the A site introduced by Puglisi and Yokoyama.89, 91
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1.5

The Ribosome as a Drug Target
The ribosome serves as an attractive drug target for a variety of reasons. First of all, it is

composed of diverse structural motifs that serve as good binding sites for small molecules.36
Unlike DNA, rRNA has no known repair mechanisms and is located outside the nucleus; rRNA is
more accessible compared to DNA. The structure of the ribosome is conserved across
phylogeny; however, there still remain subtle sequence differences and conformational
variations that can be utilized for species-specific targeting of antibiotics.93 Even though there
are a wide variety of structural motifs present in the ribosome, most of the current antibiotics
target a narrow section of the ribosome with some overlapping sites, utilizing distinct modes
for protein-synthesis inhibition (Figure 1.7).94-96 Some of the modes of inhibition include
inducing miscoding,88, 95 interfering with ribosome dynamics,94, 97 competing with substrate
binding,97 blocking the peptide-exit tunnel,8 and inhibiting movement of the mRNA chain.97
The success of crystallographic studies has expanded our understanding of antibiotic
rRNA interactions such that it is not uncommon to find that one antibiotic may exerts its
inhibitory action by one major mode in addition to several minor modes due to minor or
secondary interactions with other sites on the ribosome.7, 87, 95 This is not surprising, because
some ribosomal antibiotics share common chemical elements and similar structures. Some
antibiotics that exert these different modes of inhibition are discussed below.
Aminoglycoside antibiotics, such as paromomycin, bind the ribosomal A site and induce
miscoding by increasing the initial binding affinity of non-cognate tRNA by stabilizing helix 44 in
a specific conformation.88, 95
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A)

B)

Figure 1.7: A) Structure of the 30 S ribosomal subunit shows the binding sites of current
antibiotics. This figure was generated using coordinates from PDB files 1FJG, 1HNZ, 1HNW,
1HNX, and 3KNN.94-96 B) Structure of the 50 S ribosomal subunit shows the binding sites of
current antibiotics. This figure was generated using coordinates from PDB files 1N8R, 1NJI, and
3CF5.7, 98
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Other aminoglycosides, such as kanamycin and tetracycline interact with the decoding region
and block interactions of tRNA.6, 94 Also, the aminoglycoside hygromycin B binds to helix 44 of
the 30 S subunit and has been shown to inhibit the movement of tRNA to the P site by
restricting a conformational change in helix 44 that is crucial for the translocation of tRNA.94 It
is worth noting that aminoglycosides are a class of antibiotics that have very similar structures;
however, they are able to inhibit protein synthesis by a variety of modes described above. A
more detailed description of the structure of aminoglycosides will be discussed in the next
section. Antibiotics such as clindamycin, chloramphenicol, sparsomycin, and streptogramin A
interfere with tRNA binding to the P site.99-100 Also, ketolides, macrolides, and streptogramin B
have been shown to bind to the peptide-exit tunnel and block the progression of the extending
poplypeptide.100-101 Inhibition of the ribosome has been a good avenue for developing
antibiotics. As our understanding of the structure and function of the ribosome increases, it is
expected that more potent antibiotics will be developed to counteract the resistance problem.
Recent efforts to identify new potential drug target sites in the ribosome will be discussed in
the next section.

1.5.1 New Potential Drug Target Sites
Clinically useful antibiotics target functionally important sites of the ribosome. In the
small subunit (30 S), they interfere with tRNA binding or translocation, or displace/hinder
mRNA progression during protein synthesis.6, 94, 97 In the large subunit (50 S), most antibiotics
target the peptidyl-transferase center, peptide-exit tunnel, GTPase-association center, or the
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translation-factor-binding region.99-102 The above-mentioned regions represent a very narrow
section of the ribosome considering its enormous size. This fact has prompted researchers to
explore and discover other sites on the ribosome that can serve as good drug targets. Advances
in ribosome crystallography and NMR have aided in the identification of several potential
antibiotic target sites such as helix 69 (H69) and helix 31 (h31). H69, from the large subunit of
the ribosome, is located in the inter-subunit bridge B2a region and makes important contacts
with the small ribosomal subunit, A- and P-site bound tRNAs, as well as translation factors. 103104

The small subunit hairpin h31 serves as a promising drug target because it is located near

the P site and is proposed to be involved in the decoding process. 105-107
Furthermore, advances in sequencing technology allow for identification of conserved
sequences that can be utilized as potential drug target sites. Despite the success of this process,
conservation of a nucleotide does not always correlate with its functional importance.108 This is
one drawback of the nucleotide conservation approach to identifying new drug target sites.
Using mutational studies, Mankin and co-workers have explored the prospect of finding
new potential drug target sites in the ribosome in a more random manner. Their results
identified several deleterious mutations that coincide with current antibiotic target sites, as
well as interesting new sites. In the 30 S subunit, Makin and co-workers identified a cluster of
mutation in helices 5 and 15 that moderately inhibited translation with the exception of A55G
and A373G that completely abolished translation due to interference with subunit
association.109 This section of the 30 S subunit is not part of the already identified functionally
important sites; nonetheless, it is an important player in ribosome biogenesis and this makes it
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a potential antibiotic target.109 Also a cluster of moderately deleterious mutations in the middle
portion of helix 24 were identified. This portion of helix 24 is important because it makes
contact with protein L2 and is proposed to be part of a signal pathway linking the large and
small ribosomal subunits. Similar to helices 5 and 15, deleterious mutations were identified in
helices 21 and 12. Compromising of these helices may result in hindrance of 30 S assembly,
because these helices make important contacts with the primary assembly proteins of the 30 S
subunit. Lastly, strong deleterious mutations identified in helices 35-37, which are located on
the solvent side far from all known functional sites, induced unidentified severe functional
defects not related to subunit association or the translation process itself.109 A summary of
these new potential drug target sites in the 30 S subunit is shown in Figure 1.8A.
Similarly, other potential drug targets have been identified in the large subunit (60 S)
using the same methodology.110 These sites include H38, H32, H55, H61, H19, and H20, which
were identified to contain deleterious mutations. The mutations have been proposed to result
in functional defects ranging from inhibition of 50 S biogenesis, subunit association, and
perturbation of ribosome structure, to inhibition of binding of elongation factors.110 Refer to
Figure 1.8B for the spatial location of these new potential drug target sites on the 50 S subunit.

1.6

Aminoglycoside Antibiotics
Aminoglycosides are antibiotics used to treat infections from both gram-positive and

gram-negative bacteria.111-112 The chemical structure consists of amino sugars linked to a 2-
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deoxystreptamine ring. Aminoglycosides are classified into two groups, based on how the
different sugar rings are linked to the central 2-deoxystreptamine ring.
A)

B)

Figure 1.8: A) Structure of the 30 S subunit shows current drug target sites (blue helices) and
new potential drug target sites (red helices). B) Structure of the 50 S subunit shows current
drug target sites (blue helices) and new potential drug target sites (red helices). The figures
were generated with PyMol software49 using coordinates from PDB file 3I8F and 3I8G.109-110,113
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The two classes are the 4,5-linked also known as the neomycin class, and the 4,6-linked, also
known as the kanamycin class. The conserved structural motif between these two classes is the
neamine core (Figure 1.9).114
A)

B)

Figure 1.9: Chemical structures of A) 4, 5-linked and B) 4, 6-linked aminoglycosides are shown.
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Aminoglycosides have been shown to exhibit their antibiotic activity by binding to the
16 S rRNA and inhibiting protein synthesis by a variety of modes such as inducing miscoding,88,
95

blocking interactions with tRNA,6, 94 and inhibiting the movement of tRNA to the P-site.94
Traditionally, aminoglycosides have been used to target the ribosome; however, more

recent efforts have seen the use of aminoglycosides and its derivatives to target the human
immunodeficiency virus (HIV).115-117 Aminoglycosides have been shown to bind to the transactivation responsive region (TAR) and inhibit the binding of a viral regulatory protein, known
as the trans-activator of transcription (Tat).115-117 This Tat-TAR interaction is crucial for the
successful replication of HIV-1; therefore, the binding of aminoglycosides to TAR inhibits the
propagation of HIV-1.118-120
Furthermore, premature termination codons (PTCs) have been linked to many genetic
disorders. Suppression of PTCs has emerged as an attractive treatment option for a variety of
genetic diseases.121 Aminoglycosides, such as gentamicin, tobramycin, and amikacin, have been
explored for the treatment of cystic fibrosis by inducing read-through of PTCs associated with
this disease.122-124 Although aminoglycosides have been used successfully to treat many
diseases, there are a lot of problems associated with their usage. The major problems include
toxicity, synthetic access, and bacterial resistance.
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1.6.1 Problems Associated with Aminoglycoside Therapy

1.6.1.1

Toxicity

The long-term use of aminoglycosides is discouraged because of toxicity issues
associated with this class of antibiotic. The primary toxicity effects that arise from
aminoglycoside usage are nephrotoxicity and ototoxicity.125-127 Nephrotoxicity arises from
kidney malfunction caused by accumulation of aminoglycoside compounds in the kidney.127
Aminoglycoside metabolites are eliminated by the kidney through a series of processes that
involve the transfer of aminoglycoside metabolites through the lysosome.127 The polycationic
nature of the aminoglycosides facilitates its binding to negatively charged phospholipids in the
lysosome, resulting in decreased activity of lysosomal phospholipase and eventually causes the
arrest of the aminoglycoside secretion pathway.127 This kind of aminoglycoside induced
nephrotoxicity is fully reversible upon hydration treatment; however, prolonged usage of
aminoglycosides may result in permanent damage to the kidney.
Unlike nephrotoxicity, ototoxicity is irreversible and it is characterized by vestibular
hypofunction (disorientation or dizziness due to issues of the ear) or high-frequency hearing
loss.126 These symptoms arise from degeneration of hair cells and neurons in the cochlea, which
do not regenerate once damaged. This condition is brought about by accumulation of free
radicals in the ear induced by the use of aminoglycosides. The free radicals initiate the
apoptotic pathway leading to degeneration of cochlear and vestibular cells.126, 128
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Current efforts have been geared toward the development of new aminoglycosides that
are less toxic. For example, Tulkens and co-workers have shown that placing a non-ionizable
acyl group at the N1 position reduces the binding of aminoglycosides to phospholipids, thereby
reducing the nephrotoxicity effect of these aminoglycosides.129 Also, Mazurek and co-workers
have shown that induction of heat shock protein 70 can lead to reduced ototoxicity arising from
the use of gentamycin.130 These examples show the steady progress toward developing new
aminoglycosides with reduced side effects.

1.6.1.2

Synthetic Access

Total chemical synthesis of aminoglycosides is very challenging. Current synthetic
methodologies require numerous steps resulting in very poor overall yields.131-132 Another
drawback is the lack of appropriate protection group chemistry that will allow for fewer steps in
the synthetic pathway.132 Researchers are now working on developing new methodologies that
will allow for better yields and large quantity production. One promising method is using
chemoenzymatic methods to generate large libraries of compounds.133-134

1.6.1.3

Bacterial Resistance to Aminoglycosides

There are three main mechanisms by which bacteria develop resistance against
aminoglycosides, namely: a) aminoglycoside-binding-site modification by mutation or
methylation;135 b) reduction of intracellular concentrations of aminoglycosides by modification
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of the bacterial outer membrane or by efflux;136-137 c) modification of the amino and hydroxyl
groups of the aminoglycoside by acetylation, adenylation or phophorylation.138
Many aminoglycoside-producing bacteria protect themselves by expressing rRNA
methylases that methylate the target site of the aminoglycoside in their ribosomes. This
reduces the affinity of the aminoglycoside for the ribosome target, thereby protecting the host
bacterium.139 These methylases can be transferred to other pathogenic bacteria, thereby
granting them resistance to aminoglycosides.135, 140 For example, methylation of G1405 of the
16 S rRNA confers resistance to 4,6-linked aminoglycosides.141 A summary of resistance
methlyases and the nucleotides they methylate is given in Table 1.3.
Reduction of intracellular concentrations of aminoglycosides by modification of the
bacterial outer membrane or by efflux is a major contributor to some types of antibiotic
resistance.14, 142 Changes in the bacterial membrane components can occur, resulting in poor
uptake or low interaction with aminoglycoside antibiotics, thereby leading to resistance.11, 142
Also, over-expression of ATP-dependent pumps resulting from mutations in their regulatory
genes can give rise to reduced accumulation of the aminoglycoside in the bacterial cell, thereby
reducing the effectiveness of the drug.11, 142
Aminoglycoside modification is the most common type of resistance mechanism seen in
aminoglycosides. Resistance occurs when the amino groups at positions 1, 3, 2′ and 6′ and
hydroxyl groups at positions 3′, 4′ and 2′′ are modified by aceylation, adenylation or
phosphorylation thereby rendering them inert (Figure 1.10).12
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There are three types of aminoglycoside modifying enzymes, nucleotidyl-transferases
that are ATP dependent (ANT), phosphotransferases that are ATP or GTP dependent (APH), and
acetyltransferases that are acetyl-CoA dependent (AAC).12 The aminoglycoside-modifying
enzymes are regiospecific; however, there are also bi-functional enzymes that can catalyze both
6′-acetylation and 2′-phosphorylation of its substrate.114, 143

Table 1.3: Summary of 16 S rRNA resistance methylases is given.
Resistance
methylase
RmtA
RmtB
RmtD
ArmA
RmtC
FmrO
Krm
KgmB
NbrB
Kmr
GrmA
Sgm
Srm1
GrmB
NpmA
KamB
KamA

Family
Arm
Arm
Arm
Arm
Arm
Kgm
Kgm
Kgm
Kgm
Kgm
Kgm
Kgm
Kgm
Kgm
Pam
Kam
Kam

Position
methylated
ND
G1405
ND
G1405
ND
ND
G1405
G1405
ND
ND
G1405
G1405
ND
ND
G1408
G1408
G1408

Drug resistance
conferred

Reference

Kan, Apr, 4,6-DOS

144

Kan, Apr, 4,6-DOS

13

4,6-DOS
4,6-DOS

145
139

145
145
Kan, Gen, 4,5-DOS
4,5-DOS
4,5-DOS
4,5-DOS

146
147
148

ND; not determined, Kan; kanamycin, Apr; apramycin, 4,6-DOS; 4,6-disubstituted
deoxystreptamine, 4,5-DOS; 4,5-disubstituded deoxystreptamine.
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Figure 1.10: Aminoglycoside resistance enzyme modification sites on kanamycin are shown.12

Also, researchers have recently isolated genes from S. marcescens and P. aeruginosa
that encode for bi-functional enzymes designated as AAC(3)-lb/AAC(6′)-lb′, AAC(6′)-30/AAC(6′)lb′, and ANT(3′′)-li/ACC(6′)-lld.149-152 The success of aminoglycosides has been compromised
because of the spread of the resistance enzymes. Hence, current research efforts have been
geared toward designing new aminoglycoside analogues that can evade these resistance
mechanisms.
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1.7

Tools for Exploring RNA-Ligand Interactions
A variety of techniques are used as tools for screening RNA-binding ligands. Among

them are biophysical methods such as NMR, SPR, ITC, ESI-MS, fluorescence assays, and
biochemical methods such as RNase and chemical footprinting. A general overview of these
techniques is provided below.
Nuclear magnetic resonance (NMR) is a desirable technique because it can be used to
determine the binding site and capture conformational changes that occur upon ligand binding
to the RNA target.153-154 By monitoring imino proton shifts, standard 1D NMR experiments can
be used to detect binding of ligands to RNA.155 The drawback of using NMR is that a large
amount of RNA is required to conduct experiments, and isotope labeling of the RNA or ligand
may be necessary in some experiments.
Surface plasmon resonance (SPR) employs the use of immobilized RNA on a metal
surface (chip), over which the dissolved ligand is continuously flowed. Binding is detected by
changes in the angle of refraction of incident light focused on the chip.156 Binding parameters
such as dissociation constants and on and off rates can be determined with this technique.156157

Even though low concentrations of RNA and ligand are required, SPR is not widely used

because of its high cost and low throughput nature.158
Isothermal titration calorimetry (ITC) is the gold standard for obtaining dissociation
constants and thermodynamic parameters for RNA-ligand binding.158 It operates by measuring
the heat change upon ligand binding in a closed system.159 Although it is a desirable method, its
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use is limited because it requires a large amount of RNA to conduct a single experiment, it is
low throughput, and it cannot be applied to ligands with poor solubility in aqueous solutions.158
Many techniques available today employ the use of fluorescence to monitor RNA-ligand
binding. For example there are methods that employ fluorescently end-labeled RNA or ligands.
Binding of the ligand to the RNA results in conformational changes that affect the fluorescence
of the fluorophore, thereby providing a readout for the binding event.160 This technique has
been used extensively in characterizing the binding of aminoglycosides to RNA.160-161 The
drawback with this technique is that the fluorescence change depends on how far the
fluorophore is from the binding site, and therefore cannot be applied to larger RNA
constructs.158 Assays that require fluorescently labeled ligands cannot be used for ligand
discovery because it requires a known ligand that can be fluorescently labeled. Other methods
employ the use of 2-aminopurine as a site-specific probe to monitor ligand binding events.162-163
Usually an adenine which is at, or close to, the ligand binding site is replaced with 2aminopurine, which acts as a fluorescent reporter.162-164 The disadvantage with this technique is
that the incorporated 2-aminopurine has to be close to the binding site and the presence of the
2-aminopurine may cause structural changes that may affect ligand binding.165 Fluorescent
indicator displacement is another technique which can be used to assess RNA-ligand
interactions.166-167 This technique, as well as ESI-MS, were utilized as screening tools in this
thesis work, and will be discussed in more detail in the next chapter.
Biochemical methods such as RNase and chemical footprinting are very popular
techniques used to validate ligand binding sites and obtain dissociation constants.168 These
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assays utilize end-labeled RNA (usually radio-labeled). The labeled RNA is incubated with
varying concentrations of ligand. After binding equilibrium is reached, the RNA is degraded with
RNases or chemical reagents.168 The binding site of the ligand can be identified by protection
from degradation, and binding constants can be determined by quantifying the protected
bands as a function of ligand concentration.169 These biochemical methods will also be
discussed in the next chapter.

1.7 Thesis Overview
The clinical usefulness of aminoglycosides has been compromised due to widespread
resistance to this class of antibiotics. The long-term goal of this project is to develop new
aminoglycoside antibiotics that target the A site (or other regions) of the bacterial ribosome.
The strategy is to simplify the aminoglycosides by generating derivatives of the neamine core in
order to maintain the minimal motif for binding, but avoid enzymatic modification.To achieve
this goal, a series of compounds were synthesized by our collaborators and screened for their
affinity to a model A-site RNA in our laboratory. The binding site and mode of action of the top
candidates were characterized by using biochemical methods and enzymatic footprinting
(Chapter 3). The binding sites of the ligands were compared to that of the parent compounds in
order to gain insights to why the ligands had good or poor antibacterial activity. This
information will also be helpful in designing the next generation of ligands.
In the second part of the thesis work, a new high-throughput fluorescent intercalator
displacement assay was developed to aid in rapid screening of ligand libraries for RNA binding.
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The assay employed dye molecules as the fluorescent indicators. Furthermore, electrospray
ionization mass spectrometry (ESI-MS) was used to investigate the mechanism of the assay. The
assay was optimized for screening a variety of RNA-binding ligands with a set of small hairpin
RNAs (A site, TAR, h31, and H69) (Chapter 4).
The specificity of the top candidates and the parent compounds were tested against a
variety of RNA models using ESI-MS (Chapter 5). The aim was to identify ligands that prefer
certain RNA structural motifs (duplex, hairpin loop, or internal bulge), and also identify the
ligands that had significant preference for the human A-site RNA. This information will help us
to design the next generation of ligands to be more specific and less toxic.
Modified nucleotides have been well characterized for the roles that they play in
antibiotic sensitivity and resistance; however, the role that modified nucleotides play in
antibiotic binding is not well understood. In Chapter 6, the role that modified nucleotides play
in the binding of a variety of antibiotics was investigated.
An overview of the various biophysical and biochemical techniques that were used to
achieve our goals is given in the next chapter.

35

CHAPTER 2
BIOPHYSICAL AND BIOCHEMICAL METHODS
A variety of techniques were utilized in this thesis work to investigate RNA-ligand
interactions. This section will focus on providing a general background and introduction to
these techniques. Detailed experimental will be provided in the chapters that utilize these
techniques.

2.1

Mass Spectrometry Applied to Macromolecular Analysis

2.1.1 General Set-up of a Mass Spectrometer
The process of mass spectrometry analysis involves the formation of analyte ions in the
gaseous phase, followed by sorting and selection of wanted masses and finally detection of ions
by their mass-to-charge ratios (m/z). To achieve this, the mass spectrometer uses several
functional units, which consist of three main parts: the ion source, mass analyzer, and detector
(Figure 2.1).170
Depending on the ionization process, the analyte may already exist as ions in solution or
may be ionized during the volitisation process in the ion source. The ions are deflected by an
electric or magnetic field in the mass analyzer (maintained at vacuum pressure), thereby sorting
the ions according to their m/z values.170 The detector then converts the detected ions into a
proportional electric current, followed by generation of a spectrum, in which the electric
current is recorded as a function of m/z.170
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Figure 2.1: The general set-up of a mass spectrometer for molecular analysis is outlined.

2.1.1.1

Ion Source

There are different techniques used to transfer the analyte into the gas phase (Figure
2.1). For elemental analysis, very harsh techniques such as inductively coupled plasma (ICP) are
used to fragment and ionize the sample.171 On the other hand, softer ionization techniques are
used for macromolecular analysis. Matrix assisted laser desorption ionization (MALDI) is
considered to be a soft ionization process, in which the analyte is co-crystallized with a solid
matrix (for example 3-hydroxypicolinic acid) that can absorb light energy emitted from a
laser.172 Upon irradiation, the analyte is ionized by the energy transferred from the matrix.172-173
The precise mechanism by which ionization occurs in MALDI is still unknown.172 One advantage
of MALDI is that usually only singly charged ions are produced, and therefore MALDI can be
used to provide molecular weight information for more than one analyte without complicated
analyses.174
Atmospheric pressure chemical ionization (APCI) is another soft ionization process that
can be used to ionize weakly polar analytes and samples that do not exist as pre-formed ions in
solutions.170 Reagent and solvent molecules are ionized at atmospheric pressure by electrons
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from a fine needle maintained at a high voltage (~ 1-5 kV). Chemical reactions occur between
the thermally vaporized analyte and the ionized solvent or reagents, which lead to the
ionization of the sample.170 APCI has the advantage of having a reduced salt susceptibility as
compared to ESI, and therefore APCI is usually used to complement ESI.175 The mechanism of
ESI will be discussed in detail in the next section.

2.1.1.2

Mass Analyzer

After ionization, the analyte is transferred to the mass analyzer where a specific mass
range can be focused onto the detector. The quadrupole mass analyzer consists of four
cylindrical rods with radio frequency and DC current flowing through them. By tuning the radio
frequency and DC current, only ions of a certain mass range maintain a stable trajectory
through the quadrupole, whereas other mass ranges are deflected and prevented from
reaching the detector.176 Compared to all of the available contemporary mass analyzers, the
resolution of the quadrupole is very low and also has a limited mass range (usually < 4000 m/z).
In spite of its limitations, the quadrupole mass analyzer is widely used because of its relatively
low cost, low voltage requirement and small physical size.176
Sector mass analyzers utilize magnetic sectors that bend the trajectories of ions into
circular paths.177 The radii of the paths depend on the mass-to-charge ratio of the ions. This
allows only ions with certain m/z values to pass through a slit and reach the detector.175, 178
These analyzers have very high mass accuracy and resolution; however, magnetic sectors are
not widely used because of their high cost and enormous size.175
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A time-of-flight (TOF) mass analyzer sorts ions by applying a fixed potential to a pulse of
ions generated from the ion source.170 The potential imparts kinetic energy to the ions and
accelerates them through a drift region with a set distance. Since the potential energy delivered
is constant, ions with a smaller size obtain greater kinetic energy and therefore travel through
the drift tube faster.170 The m/z of the ions is determined by measuring the time it takes for the
ions to reach the detector. Usually TOF analyzers are operated with reflectrons. These are
electrostatic mirrors that send the ions along a second flight distance toward the detector. The
use of the reflectron helps to compensate for any discrepancies in velocities of ions with the
same m/z arising from the ionization process.175 TOF mass analyzers can achieve higher
resolutions as compared to the quadrupole, and can also achieve mass accuracy up to 50
ppm.179
Fourier transform ion cyclotron resonance (FTICR) mass analyzers employ the use of a
magnetic field.175 Analyte ions are transferred into the magnetic field with a low velocity, and
hence they become trapped in the magnetic field instead of deflected as in the case of sector
analyzers. The trapped ions are excited by an electric field held perpendicular to the magnetic
field causing the ions to oscillate with covalent orbital (cyclotron) frequencies inversely
proportional to their m/z values. The oscillating frequencies of the ions are converted to m/z
readings using a Fourier transform.175 FTICR is the most powerful instrument available for
accurate mass determination; its resolution power is in the high parts per billion.175
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2.1.2 Application of ESI-MS to Nucleic Acids
Electrospray ionization (ESI) is the method of choice commonly used for the ionization
of biological molecules such as nucleic acids, peptides, and proteins. This is because it is a soft
ionization process that allows for analyte detection with minimal fragmentation.180 ESI-MS was
first applied to the detection of non-covalent interactions in 1991.180 Since then, ESI-MS has
been extended to the study of non-covalent interactions between nucleic acids and ligands as a
screening tool for drug discovery.181-182 ESI-MS allows for examination of multiple-stoichiometry
complexes, even at very low abundance. 183

2.1.2.1

Mechanism of Electrospray Ionization

In ESI, ions are generated by passing the analyte through a small heated capillary
maintained at high voltage (~4.5 kV). A continuous flow of an inert gas such as nitrogen is used
to facilitate nebulization of the sample, allowing it to emerge from the tip of the capillary in an
aerosol of charged droplets (Figure 2.2).182 The polarity of the droplets depends on the sign of
the applied voltage. For nucleic acids, the negative ion mode is used, such that positive charges
are removed from the capillary wall and negative charges are drawn toward the liquid front as
the analyte emerges from the capillary.182 Following nebulization, the solvent around the
charged droplets evaporates as they travel to the mass analyzer, which reduces the size of the
droplets to a point where Coulomb repulsion forces between the charged droplets are very
high, causing them to break into even smaller droplets. This process continues to a point where
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single ions are isolated, surrounded by residual counter ions such as Na+. The analyte ions are
then passed through a skimmer and toward the mass analyzer (Figure 2.2).

Figure 2.2 A schematic diagram of the electrospray ionization process is shown.

ESI-MS has a low salt tolerance; therefore, even minute amounts of sodium or
potassium ions will condense on nucleic acids during droplet formation, resulting in detection
of a wide distribution of salt adducts, which drastically reduces the resolution and complicates
data analysis.182 To solve this problem, ammonium acetate is usually used as the buffer. In the
negative ion mode, droplets of negatively charged RNA polyanions can be neutralized by proton
transfer from NH4+ to PO- of the RNA backbone. Using a solution with 150 mM ammonium
acetate usually results in a small fraction of phosphates that remain negatively charged (on
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average, 5 out of 22 in a 12-mer duplex DNA).182 When analyzing nucleic acids with ESI-MS, a
volatile solvent such as isopropyl alcohol (IPA) or methanol is usually added to the sample prior
to injection. Presence of the alcohol decreases the surface tension of the droplets and favors
droplet formation. It also gives a significant signal enhancement (Figure 2.3) and helps minimize
the risk of analyte conformational changes in solution.182

Figure 2.3: ESI-MS spectra show signal enhancement upon increasing concentrations of
isopropyl alcohol (IPA) with a representative RNA molecule and RNA-binding ligand.
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2.1.2.2

Determination of Equilibrium Binding Constants

ESI-MS can be used for quantitative measurements. The position of the peaks in a mass
spectrum allows for the determination of stoichiometries of complexes that are present in the
sample. By monitoring the relative intensities of sample peaks, ESI-MS can be used to perform
binding assays to determine equilibrium dissociation constants, and can also be used to
perform competition assays provided that the ligands being used do not have overlapping m/z
signals.

2.1.2.3

Binding Assays

One method for determining equilibrium binding constants is to perform a binding assay
to obtain seven or more data points to generate a binding curve. Generally, different
concentrations of ligand ranging from low to high depending on the estimated Kd of the ligand
are allowed to equilibrate with a constant concentration of RNA (~ 1 µM) in 150 mM
ammonium acetate. Right before injection, 50% IPA is added to the sample and the sample is
infused into the instrument. Sixty scans per sample are taken and averaged.

2.1.2.4

Obtaining Binding a Curve

Each spectrum is smoothed, integrated, and the area under each peak is calculated
using Masslynx (Micromass Ltd. Manchester, UK). A plot of ligand concentration vs fraction of
ligand bound is generated. The faction of ligand bound (Fr) is calculated using the equation; Fr =
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RL / R + RL, in which RL is the peak area of RNA-ligand complex, and R is the peak area of free
RNA.
The peak areas of the different species are proportion to their concentrations in solution.184

2.1.2.5

Curve Fitting

One advantage of ESI-MS is that the stoichiometry of the non-covalent complex of
interest can be determined directly by the location of the peaks on the mass spectrum. With
the stoichiometry already known, the curve can be fitted to the appropriate binding model. For
a 1-to-1 binding assay expressed in the form RL

R + L, a quadratic equation is derived as

follows to fit the data:
The dissociation constant, Kd, can be expressed as:

in which R is the concentration of free RNA, L is the concentration of ligand, and RL is the
concentration of RNA-ligand complex.
But,

In which Rf is the concentration of free RNA, Lf is the concentration of free ligand, Rt is the
concentration of total RNA, and Lt is the concentration of total ligand.
Therefore,
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Both sides are multiplied by RL to give:

The equation is expanded to give:

After rearrangement,

and solving for x,

Hence,
Equation 1

Equation 1 is used to fit binding curves describing a 1:1 binding model.184
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2.2

Fluorescence Spectroscopy
Fluorescence is a phenomenon that describes the light energy emitted by a molecule

that falls from an excited singlet state to various vibrational levels of the electronic ground
state.185 The fluorescence intensity of a molecule at a given wavelength carries information
about the physical and chemical nature of the molecule’s microsurroundings. Fluorescence
emission is one of several processes by which an excited molecule can release energy. Others
include non-radiative processes such as internal conversion, vibrational relaxation, intersystem
crossing and longer-lifetime relaxation from the triplet state to the ground state known as
phosphorescence (Figure 2.4).186 Other relaxation processes include collisional quenching,
solvent relaxation, energy transfer, and photochemical reactions.186 The fluorescence intensity
and quantum yield (the fraction of excited molecules that undergo fluorescence) can be
influenced by any interactions of the fluorescing molecule which can favor the other competing
relaxation processes or can introduce a new relaxation pathway. Therefore, careful
characterization of the experimental system is necessary in order to ensure accurate
interpretations of the data acquired. The basic set-up of instrumentation for fluorescence
detection is shown in Figure 2.5. Fluorescence spectroscopy can be applied to a wide range of
problems in biology and biochemistry. Fluorescence measurements can provide information
about molecular processes including binding interactions,187 conformational changes,188 and
distances between two sites on a biomolecule.189 More advanced fluorescence techniques can
achieve very high resolutions, even up to single molecule detection.190-191
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Figure 2.4: A Jablonski diagram shows the different relaxation processes that an excited
molecule can undertake after absorption (ABS) of energy. The relaxation processes include
fluorescence (FL), phosphorescence (PH), vibrational relaxation (VR), internal conversion (IC),
and intersystem crossing (ISC). The single and triplet states are designate as S0-S2 and T1
respectively.

Figure 2.5: Basic instrumentation for fluorescence detection is represented.
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2.2.1 Fluorophores
Fluorophores or fluorescent dyes are molecules that can absorb light at a specific
wavelength and emit light at a longer wavelength upon relaxation.185 The chemical structure of
fluorescent dyes usually consists of conjugated functional groups or aromatic rings (Figure 2.6).
The delocalized electrons in such structures absorb energy and stabilize the molecule in the
excited state.185 Fluorophores can absorb and emit light over and over again; however, in some
instances the structure of the fluorophore can be damaged and it will not be able to fluoresce
any longer.185 This process is known as photobleaching, and it is important to check for
photobleaching when performing fluorescence experiments. The planar structure of most
fluorophores makes them very good intercalating agents, and they are therefore widely used as
nucleic-acid- staining agents.

Figure 2.6: The chemical structures of some common fluorophores are shown.
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2.2.1 Fluorescence Intercalator Displacement
Fluorescent intercalator displacement assay is based on the theory that a fluorescent
probe bound to RNA is displaced by a ligand, leading to reduction in fluoresce intensity. The
extent of decrease in fluoresce is proportional to the affinity of the ligand for the RNA (Figure
2.7). The structure of B DNA provides a wide and deep major groove that allows for
intercalation of dyes.158 Unlike DNA, RNA has a narrow and deep “major groove” that is not
conducive for intercalation. Therefore, a number of dyes that readily intercalate into DNA do
not bind to RNA.158 In spite of this drawback, unpaired or mismatched bases in RNA provide
binding pockets for small molecules and fluorephores.158 In this thesis work, an assay based on
DNA fluorescent intercalator displacement was developed to assess and rank the binding
affinity of ligands to RNA.

Figure 2.7: The FID assay is summarized. The degree of reduction in fluorescence intensity
correlates to the affinity of the compound for the RNA.
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2.2.1.1

General Procedure for RNA FID Using TO-PRO

The generalized instrumentation set-up for the experiment is shown in Figure 2.5. A
range of dyes may be appropriate, but the discussion will be limited to a single dye. 3-Methyl-2((1-(3-(trimethylammonio)propyl)-4-quinolinylidene)methyl)benzothiazolium

(TO-PRO)

has

essentially no fluorescence when free in solution, but exhibits a 400-fold increase in
fluorescence when bound to RNA such as the A site (Figure 2.8). Initially, the optimal excitation
and emission wavelengths of the dye are determined by generating an absorption and emission
profile. For example, the excitation and emission wavelengths of TO-PRO were determined to
be 512 nm and 533 nm, respectively, at room temperature in 100 mM KCl and 20 mM Tris-Cl pH
7 (Figure 2.9). Next, the dye is titrated into a constant concentration of RNA to determine the
appropriate concentration of dye needed to provide the highest fluorescence signal. At this
concentration of dye, it is assumed that all of the binding sites of the RNA are occupied by dye
molecules. This dye:RNA ratio is then used for the screening experiments. For this study, all
fluorescence readings were taken on a Cary Eclipse Spectrophotometer (Varian Inc., Walnut
Creek, CA). Typically, 2 µM of RNA is incubated with 2 µM of TO-PRO in 100 mM KCl and 20 mM
Tris-Cl, pH 7, for 5 minutes. The initial fluorescence reading is taken and the appropriate
concentration of drug is then added, mixed thoroughly, and allowed to equilibrate for another
5 minutes. Five scans per sample are taken with an excitation wavelength of 512 nm (5 nm slit
width). The level of fluorescence change (either enhancement or quenching) is determined and
converted to a percent change in fluorescence using the formula (F1/F0)*100, in which F0 is the
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initial fluorescence of dye bound to RNA before the addition of drug and F1 is the fluorescence
after addition of drug.
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Figure 2.8: Fluorescence enhancement of the TO-PRO dye after association with 1 µM A-site
RNA is shown. In this case, excitation occurred at 510 nm and emission was monitored between
520 and 600 nm.
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Figure 2.9: An overlay of the excitation and emission profiles of TO-PRO is shown.
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2.3

RNA Probing
A wide variety of chemical probes are available for obtaining distinct information about

RNA structure. Among them are base-specific reagents that carry out methylations or
alkylations with one or more of the four RNA bases. They provide structural information about
hydrogen bonding, base stacking, and electrostatic environments close to the position of
modification on the base.192 Examples of these chemical probes include dimethyl sulfate (DMS),
which modifies N7 of guanine, N1 of adenine and N3 of cytosine,193 diethylpyrocarbonate
(DEPC), which modifies N7 of adenine,193 and hydrazine, which modifies uracils and
preferentially modifies cytosine at high salt concentrations.192-195 Furthermore, sequence and
base-specific restriction enzymes such as RNase A, RNase T1, and RNase V1, just to mention a
few, can be used as footprinting probes to determine the binding sites of small molecules on
RNA. Brunel and Romby provide a good review of chemical and enzymatic probes that are
employed in RNA sequencing and footprinting applications.192
RNA probing with chemical reagents and enzymes is performed in such a way that only a
limited amount of the RNA is modified. The modifications can result in either RNA cleavage that
can be detected by polyacrylamide gel analysis of end-labeled RNA or covalent modification of
the RNA that can be detected as primer extension stops by reverse transcriptase.196 By utilizing
these techniques, one can gain more understanding about the binding sites and modes of
action of different compounds such as antibiotics.197 The next section provides a discussion of
the mechanisms of the chemical probes used in this thesis work.
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2.3.3 DMS Reaction
The N7 cyclic amine of guanosine in a single- or double stranded A-form RNA is usually
accessible for methylation by DMS unless it is involved in tertiary interactions or non WatsonCrick base pairing.198 Addition of a methyl group on the N7 position by DMS generates a
positive charge that weakens the 7,8-double bond, which can easily be reduced by sodium
borohydride (Figure 2.10).198 The resulting methylated dihydroguanosine hydrolyzes, and
provides a site for aniline to react.198

Figure 2.10: The mechanism of DMS reaction is shown. Refer to the text for the description of
the reaction process.

2.3.2 Aniline Reaction
Reaction with DMS leads to hydrolysis of the glycosidic bond between the base and
ribose, which leads to formation of a ribose tautomer.198 Formation of the open ring tautomer
can be encouraged by maintaining the reaction at 60 °C.192 The aldehyde group of the tautomer
reacts with aniline and the 3′-phosphodiester bond is cleaved by β-elimination (Figure 2.11).193
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Figure 2.11: The mechanism of aniline reaction is shown. Refer to the text for the description of
the reaction process.

2.3.3 DEPC Reaction
Diethylpyrocarbonate modifies the N7 position of adenosine. Carbethoxylation of N7 of
adeninosine destroys the resonance of the heterocyclic ring, leading to ring opening between
N7 and N8, thereby creating a site for strand scission by aniline (Figure 2.12).198-199 The reaction
with aniline proceeds as described in Section 2.3.2.

Figure 2.12: The mechanism of DEPC reaction is shown. Refer to the text for the description of
the reaction process.
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2.3.4 Hydrazine Reaction
Hydrazine attacks uridine at C-4 and C-6, opens the pyrimidine ring and forms a new 5membered ring. Further reaction leads to release of the pyrazolone ring, leaving a hydrazone
product exposed for aniline attack (Figure 2.13).194, 200 The reaction with aniline proceeds as
described in section 2.3.2.

Figure 2.13: The mechanism of hydrazine reaction is shown. Refer to the text for the
description of the reaction process.

The chemical probes discussed above were used to gain some insights to the binding
sites and mode action of the single-ring neamine analogues designed in this thesis work. A
detail experimental will be provided in the chapters in which these chemical probes are utilized.
The next chapter addresses the first objective of the project, characterizing the binding of
single-ring aminoglycoside analogues to the A site.
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CHAPTER 3
SMALL MOLECULES TARGETING THE RIBOSOMAL AMINOACYLTRANSFER
SITE*
3.1

Abstract
The structure of the aminoglycoside neamine was used as the basis for design of new

small molecules targeting the amino-acyltransfer site (A site) of the bacterial 16 S ribosomal
RNA. A series of molecules of such design was tested for binding to a model RNA representing
the A site. Several of the synthetic analogues with low molecular weights were found to bind to
the RNA with affinities comparable to the parental aminoglycoside neamine, with apparent
dissociation constants in the low micromolar range. Footprinting experiments revealed that one
of the compounds (DHR23) has a similar binding site as the antibiotic paromomycin. DMS
chemical probing also revealed that the binding of DHR23 to the A site leads to the stabilization
of the stacked in conformation of A1492 and A1493. The use of these minimal single-ring motifs
for further design and modulation of RNA-binding activity could prove fruitful for generation of
new antibiotics that would survive the action of the existing antibiotic-resistance mechanisms.

* This work has been submitted for publication. Partially carried out by Pei-Wen Chao.201
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3.2

Introduction
Aminoglycosides are antibiotics that bind to the A site of the ribosome and inhibit

proteins synthesis.202-204 The chemical structures of aminoglycosides consist of amino sugars
linked to a 2-deoxystreptamine ring (ring II). There are two classes of aminoglycosides, the 4,5linked (such as neomycin) and the 4,6-linked (such as kanamycin), in which the conserved
structural component between them is the neamine core, containing rings I and II (Figure
3.1).114 Although aminoglycosides are effective antibiotics, their use has been compromised
because of wide-spread resistance to this class of antibiotics.114 Resistance to aminoglycosides
can occur in a variety of ways; however, the most common type is enzymatic modification of
their hydroxyl and amino groups, which affects the ability of the compounds to bind to the
target RNA.114, 205 The mechanism of action and resistance to aminoglycosides antibiotics were
discussed in Chapter 1.
Data from X-ray crystal and NMR structures have revealed specific interactions between
aminoglycosides and the A site of the decoding region of 16 S rRNA (Figure 3.2).6, 95, 206-209 Due
to extensive contacts with the A site, rings I and II appeared to contain the minimal structural
components for specific binding of both classes of aminoglycosides. Recent strategies to
overcome resistance include simplifying the structures of aminoglycosides by generating
derivatives of the neamine core210-216 in order to maintain the minimal motif for ribosome
binding, but avoid enzymatic modification. For example, semi-synthetic aminoglycoside
derivatives such as amikacin contain a γ-amino-α-hydroxybutyryl group at N1 position (Figure
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3.1).217-218 This modification makes amikacin less susceptible to certain resistance enzymes,
compared to other aminoglycosides.219-220 Other studies identified a series of neamine core
analogues that had comparable or better antimicrobial activities and binding affinities than the
clinically used aminoglycosides (Figure 3.1).212-213 Also, the potential efficacy of some neamine
derivatives are increased by attachment of different lengths of polyamine groups at the O6
position of ring II. This is because the presence of the polyamine group enhances interactions
with the phosphate backbone of RNA.212-213

Figure 3.1: The chemical structures of paromomycin (4,5-linked), kanamycin (4,6-linked),
amikacin, neamine derivatives, and neamine core are shown.
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Figure 3.2: A model representing the decoding region A-site RNA is shown. The RNA is
numbered based on E. coli 16S rRNA. B) Structure shows rings I and II from kanamycin
complexed with a model A-site RNA.221 Nucleotides that make contact with ring I are shown in
blue and those that contact ring II are shown in orange. Hydrogen bonds are indicated by
dashed lines. The Figure was generated with PyMol software222 using coordinates from PDB file
2ESI.221

A series of compounds was synthesized (by Dr. Mobashery’s lab) based on the chemical
structure of neamine. The compounds were investigated in order to understand the roles of the
individual rings in binding to the decoding region A-site model and also gain insights to the
effect of various functional groups such as polyamine and γ-amino-α-hydroxybutyryl groups at
different positions of the ring I moiety. It was anticipated that these derivatives would maintain
the minimal structural motif for RNA binding, but at the same time, prevent modification by the
resistance enzymes. The neamine analogues were screened by Pei-Wen Chao using
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electrospray ionization mass spectrometry (ESI-MS).201 The results she obtained indicated that
charge formation at the N1 and N6 positions is important for binding to the A-site RNA. Also
placing an amino group at the N2 position did not seem to contribute significantly to binding.
Aminohydroxybutyryl and polyamine groups at position one enhanced binding (Figure 3.3).
Furthermore, placing a second hydroxybutyryl group at position six reduced binding to the Asite RNA. The single-ring neamine analogue with the best affinity to the A-site RNA was DHR23
(Kd ~ 10 µM) (Figure 3.3).

Figure 3.3: The effects of coupling various functional groups to ring I are shown. The apparent
Kd values were determined by using ESI-MS in 150 mM ammonium acetate buffer, pH 7.6, with
50% isopropyl alcohol.201
In this study, the binding of DHR23 to the A-site RNA was further characterized using
ESI-MS and footprinting assays. Salt and pH-dependence studies were performed to investigate
the interactions that favor the binding of DHR23 to the A-site RNA. Also, the binding site and
mode of action of DHR23 were investigated using footprinting and primer extension assays.
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3.3

Experimental

3.3.1 RNA Synthesis and Purification
The A-site RNA hairpin with the sequence 5′-GGCGUCACACCUUCGGGUGAAGUCGCC-3′,
was purchased from Dharmacon Research Inc. (Lafayette, CO). The 2′-O-ACE-protected RNA
was deprotected by incubating in tetramethylethylenediamine acetate buffer (TEMED-acetate)
(pH 3.8) for 30 min at 60 °C.223 The RNA was purified by electrophoresis on 20% denaturing
polyacrylamide gels, followed by electroelution with 1/2× TBE (45 mM Tris-HCl, 45 mM boric
acid, 1.25 mM Na2EDTA, pH 8.3) in an Amicon centrilutor. The RNA was desalted by ethanol
precipitation using a final concentration of 2 M ammonium acetate buffer, pH 7.8 (RNA for ESIMS experiments) or 0.3 M sodium acetate pH 4.5 (RNA for enzymatic reactions). The
concentration of the RNA was determined using Beer’s law with the single-stranded extinction
coefficients ( ε260 nm) of 253,390 M-1cm-1.224 For ESI-MS experiments, the A-site RNA (100 µM)
was re-natured in 100 mM ammonium acetate, pH 7.6, by heating to 95 °C for 5 min in a heat
block and slowly cooling to room temperature.

3.3.2 Neamine Analogue
DHR23 was obtained from Shahriar Mobashery and Dusan Hesek (University of Notre
Dame). It was dissolved in double-distilled water to generate 2.5 mM stock solutions for all of
the analyses.
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3.3.3 Electrospray Ionization Mass Spectrometry
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on a
Quattro LC tandem quadrupole mass spectrometer equipped with electrospray ionization in the
negative ion mode (Micromass, Manchester, UK). The samples were injected via a Harvard 11
syringe pump at a flow rate of 6 µL/min. The following tuning parameters were used: capillary
voltage 2.5 kV, cone voltage 50 V, extractor voltage 2 V, RF lens voltage 0.6 V, source block
temperature 100 °C, and disolvation temperature 120 °C. The RNA-ligand samples were
prepared in 150 mM ammonium acetate, pH 7.0. To aid sample disolvation, isopropyl alcohol
was added to the samples to achieve a 1:1 (isopropyl alcohol: sample) solution prior to
injection. In varying ionic strength experiments, 1 μM RNA was incubated with 10 μM of DHR23
in different ammonium acetate concentrations (80–225 mM) for 10 min before each
measurement. The pH-dependece experiments were carried out in 150 mM ammonium acetate
buffers at pH 5.5 to 8.6. Sixty scans per sample were taken and averaged. The spectra obtained
were smoothed and the area under each peak was calculated using Masslynx (Micromass Ltd.
Manchester, UK). The percentage of the different complex peaks were calculated using the
formula (CP/ (∑Cp + RNA)) * 100, in which Cp is the peak area of the complex (including all salt
adducts), RNA is the peak area corresponding to the free RNA and its salt adducts, and ∑Cp is
the summation of the peak areas corresponding to all complex peaks (including all salt
adducts).
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3.3.4 Transcription of 16 S rRNA
The 16 S rRNA was transcribed from vector pWK1 (Figure 3.4),225 which was graciously
provided by Dr. Phil Cunningham of Wayne State University. The pWk1 was first linearized by
using restriction enzyme BSU 36I (New England Biolabs, Ipswich, MA). Approximately 10 µg of
plasmid DNA was incubated with 1x NEB buffer 3, 1x BSA (provided with the enzyme), and 10
units of BSU 36I in a reaction volume of 100 µL. The sample was incubated at 37 °C for 4 hours.

Figure 3.4: The map of the pWK1 plasmid is shown.

The digested product was verified by running a 1% agarose gel. Next, 1.5 µg of the linearized
plasmid was used for a 100 µL transcription reaction which contained 1x reaction buffer (80
mM Hepes-KOH pH 7.5, 12 mM MgCl2, 2 mM spermidine), 40 mM dithiothreitol, 2.5 mM NTPs,
and 40 u of T7 polymerase. Inorganic pyrophosphatase (5 u/mL) was added to improve the
yield.226 The reaction was incubated at 37 °C for 5 hours and the transcription product was
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verified by running a 1% agarose gel. Finally, the transcription product was purified using sizeexclusion chromatography. Before purification, the plasmid DNA in the transcription reaction
was digested using DNase 1 (New England Biolabs, Ipswich, MA) in a 100 µL reaction that
contained six units of DNase 1, 1x reaction buffer (10 mM Tris-HCl pH 7.6, 2.5 mM MgCl2 , 0.5
mM CaCl2 ) and 87 µL of transcription product, which contained about 1.5 µg of plasmid DNA.
The transcription product was then purified using pre swollen-Sephacryl 200 HR (Sigma Aldrich,
St. Louis, MO). The resin was loaded in a Pasteur pipette to obtain a bed height of about 6 cm.
Next, the resin was equilibrated with about 6 mL of running buffer (20 mM Hepes pH 7.5 or 20
mM Tris-HCl pH 7.5) and a 100 µL sample volume was loaded onto the column. The column was
run at an approximate rate of 10 drops per minute and 0.3 mL fractions were collected. The
fractions were checked for the presence of RNA using UV absorbance and the concentration of
16 S was determined using Beer’s law and an extinction coefficient of 15,291,800 M-1cm-1.

3.3.5 3′-32P Radiolabeling
Radiolabeling of the 3′ end of the A-site RNA was achieved by using 5′- 32P [pCp] (PerkinElmer, Waltham, MA).227 In general, 25 pmoles of purified RNA was incubated in 1x T4 RNA
ligase buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM dithiothreitol, pH 7.8), 10%
dimethyl sulfoxide, 20 µCi of 5′- 32P [pCp] and 20 units of T4 RNA ligase (New England Biolabs,
Ipswich, MA) in a reaction volume of 30 µL at 4 °C for 4 hours. The reaction was quenched by
addition of 3 M ammonium acetate, followed by ethanol precipitation using 5 µg of tRNAPhe as
co-precipitant.

64

3.3.6 5′-32P Radiolabeling
Radiolabeling of the 5′ end of the DNA primers were achieved by using 32P-γ ATP (PerkinElmer, Waltham, MA). In general, 25 pmoles of the DNA was incubated in 30 µL reaction
containing 1x PNK buffer (70 mM Tris-HCl, 10 mM MgCl2, 5 mM dithiothreitol, pH 7.6 at 25 °C),
10 µCi of

32

P-γ ATP and 20 units of T4 PNK (New England Biolabs, Ipswich, MA). The reaction

was incubated at 37 °C for 30 minutes and quenched with 10 µL of 7.5 M ammonium acetate.
The labeled sample was purified using a G-25 microspin column (GE healthcare, Piscataway,
NJ).

3.3.7 RNA Chemical Probing

3.3.7.1

G Reaction

Dimethylsulfate (DMS) methylates N7 position of guanine, N1 position of adenine and
N3 position of cytosine. Modification of adenines can be detected by primer extension (blocks
the progression of reverse transcriptase); however, modification of guanines can only be
detected after further reduction reaction with NaBH4 followed by aniline treatment, which
leads to strand scission.193, 198 Truncated products can be detected by reverse transcription.193
For the G reaction, 1 µg of 16 S rRNA or 1,000,000 cpm of labeled RNA was incubated with 1
mM DMS (Sigma Aldrich, St. Louis, MO) in a 300 µL reaction volume containing 10 mM MES
buffer pH 7 and 100 mM KCl. For the end-labeled A-site RNA, 5 µg of tRNAphe was added to the
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reaction. The reaction was then incubated at 90 °C for 60 seconds and quenched by addition of
1.5 M sodium acetate followed by ethanol precipitation.
The dry RNA pellet obtained after ethanol precipitation was re-suspended in 10 mL of 1
M Tris-HCl (pH 8.2) and kept on ice. Next, 10 µL of freshly prepared 0.2 M NaBH4 was added to
the RNA sample and incubated on ice for 30 minutes. The reaction was quenched by ethanol
precipitation with 0.3 M sodium acetate (pH 4.5) and dried down. Next, 40 µL of 1 M aniline
acetate buffer (pH 4.5) was added to the dry RNA sample and incubated at 60 °C for 30 minutes
protected from light. The sample was placed in dry ice to quench the reaction and the aniline
was removed from the sample by two rounds of dissolving in water, freezing and lyophilizing.

3.3.7.2

A Reaction

Adenine specific reaction was achieved by using diethylpyrocarbonate (DEPC) (Sigma
Aldrich, St. Louis, MO).228-229 One microgram of 16 S rRNA or 500,000 cpm of radio labeled Asite RNA was incubated with 1 µL of DEPC in 200 µL of buffer containing 50 mM of sodium
acetate (pH 4.5) and 1 mM EDTA for 5 minutes at 90 °C. For the end-labeled A-site RNA, 5 µg of
tRNAPhe was added to the reaction mixture. The reaction was quenched with 5 M ammonium
acetate followed by ethanol precipitation. A second ethanol precipitation was performed using
sodium acetate, followed by aniline treatment as described for the G reaction. The mechanism
of this reaction was discussed in Chapter 2.
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3.3.7.3

U Reaction

The U reaction was performed using 97% hydrazine (Sigma Aldrich, St. Louis, MO).228-229
Ten microliters of hydrazine was added to the dry RNA sample (1 µg of 16 S rRNA or 500,000
cpm of end-labeled RNA) and incubated on ice for 10 minutes. The reaction was terminated
with 200 µL of 0.3 M sodium acetate, followed by ethanol precipitation. A second round of
ethanol precipitation was performed and the sample was dried in the speed vac. Next, the
sample was subjected to aniline treatment as described previously. The mechanism of this
reaction was discussed in Chapter 2. The chemical modifications in the 16 S rRNA were
detected using a primer extension assay.

3.3.8 Primer Extension
The dry 16 S rRNA sample modified by DMS, DEPC or hydrazine was dissolved in water
and quantified using UV absorption spectroscopy. Approximately 0.5 µg of the RNA was
incubated with 20 pmol or 200,000 cpm of 5′-labeled DNA primer in a total volume of 5 µL. The
sample was heated to 90 °C for two minutes and slowly cooled down to room temperature to
allow the primer to anneal.228-229 Next, the annealed sample was incubated with 1x reaction
buffer (50 mM Tris-HCl, pH 8.3, 60 mM NaCl, 10 mM dithiothreitol,) 3 mM MgCl2, 1 mM DNTPs,
and 10 units of AMV reverse transcriptase (Promega, Madison, WI), in a 20 µL reaction volume.
The reaction was incubated at 42 °C for one hour. For sequencing reactions, four samples were
prepared containing the appropriate ddNTP at a ratio of 1 ddNTP to 10 dNTP (2.5 mM dNTP :
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0.25 mM ddNTP). The reactions were terminated by addition of 2 mL of loading dye, boiled for
two minutes and quickly cooled on ice. The reactions were resolved on an 8 % denaturing PAGE
gel.

3.3.9 Enzymatic Footprinting
Enzymatic footprinting was carried out by incubating 3'-32P-labeled A-site RNA
(~250,000 cpm) with various concentrations (0–100 µM) of the drug being investigated in
buffer containing 10 mM Tris-HCl, pH 7.2, 15 mM NaCl, and 1 mM Na2EDTA at 37 °C for 1.5 h.
Next, 0.002 U of RNase A was added to the RNA and the mixture was incubated at 37 °C for 30
minutes. The reactions were stopped by placing the samples on dry ice, followed by denaturing
in a boiling water bath for 2 min in the presence of 1× formamide loading buffer (6× stock
solution of loading buffer contains 0.1% bromophenol blue, 0.1% xylene cyanol, 80%
formamide, and 20% glycerol). The A, U, and G sequencing ladders of the RNA were generated
as described previously (3.3.7.1-3.3.7.3). The reaction samples (50,000 cpm/each) were loaded
onto a pre-run 20% denaturing polyacrylamide gel and run at 1800 V for 3 h. The gel was
exposed overnight at -20 °C to a storage phosphorscreen, which was then scanned on a
Typhoon (GE, Piscataway NJ) phosphorimager.
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3.4

Results and Discussion

3.4.1 Effects of Ionic Strength and pH on Binding of DHR23 to A-Site RNA
DHR23 had the highest affinity to the A-site RNA relative to the other single-ring
aminoglycoside derivatives. It is expected to have a charge of +3 or +4 at neutral pH. We
hypothesized that the binding of DHR23 to the A-site RNA is mainly driven by electrostatics. To
verify this, the effects of ionic strength and pH on the relative affinity of DHR23 to A-site RNA
were examined. In this experiment, A-site RNA and 10 uM DHR23 were incubated at different
ammonium acetate concentrations (80 mM to 225 mM, pH 7.6) and varying pH values (150 mM
ammonium acetate, pH 5.5 to 8.6) and analyzed by ESI-MS. The competing ammonium ions
were expected to reduce binding of DHR23 to the A-site RNA, if the interactions were mainly
driven by electrostatics. Increasing ionic strength reduced the amount of both 1:1 and 2:1
(DHR23: A site) complex (Figure 3.5). The amount of 3:1 complex was minimal or negligible in
all cases. The ratio of 1:1 to 2:1 complexes increased with increasing ammonium ion
concentration, suggesting a greater role for electrostatics in higher order complex formation
(Figure 3.5).
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Figure 3.5: ESI-MS spectra in the m/z range of 1700-2000 of A-site RNA complexed with DHR23
at various concentrations of ammonium acetate (80 to 225 mM) at pH 7.6 are shown. The free
RNA and 1:1, 2:1, and
nd 3:1 complexes (DHR23:A
(DHR23:A-site RNA) are in the -5
5 charge state.

A similar trend was observed in experiments to determine the pH-dependence
pH
of
complex formation. Raising the pH from 7.6 to 8.6 led to a reduction of both 1:1 and 2:1
complexes, and the 3:1 complex was not observed (Figure 3.6).. A lowering of pH to 5.5 led to
increased binding. These results suggest that there is a significant electrostatic component to
the binding of DHR23 to the A-site
A
RNA. These results are summarized in Table 3.1
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Figure 3.6: ESI-MS spectra of A-site RNA complexed with DHR23 at various pH values (5.5 to
8.6) are shown. The free RNA and 1:1, 2:1, and 3:1 complexes (DHR:A-site RNA) are in the -5
charge state.
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Table 3.1: Effects of pH and ionic strength on A-site RNA binding by DHR23.

[ammonium acetate]
80 mM
150 mM
225 mM
150 mM
150 mM
150 mM
150 mM

pH
7.6
7.6
7.6
5.5
6.6
7.6
8.6

free RNA
(%)
41
60
78
27
57
60
69

1:1 complex
(%)
39
31
20
42
33
31
23

2:1 complex
(%)
16
9
2
26
8
9
7

3:1 complex
(%)
4
0
0
5
1
0
0

3.4.2 Binding Site of DHR23 on the A-site RNA
Previous ESI-MS competition studies performed by addition of paromomycin to preformed DHR23-A-site RNA complex revealed that DHR23 has a similar binding site on A-site
RNA as paromomycin.201 To locate the binding site of DHR23 on the A-site RNA, enzymatic
footprinting analysis with RNase A was performed. RNase A catalyzes the cleavage of the
phosphodiester bond in single-stranded RNA via a 5′ RNA-2′-3′ cyclic phosphate intermediate,
eventually resulting in 3′ RNA-OH and 5′ RNA-PO4 products.230 In general, 3′-radiolabeled A-site
RNA was incubated with varying concentrations of ligand and allowed to equilibrate. The
samples were treated with RNase A for 30 minutes. The idea here is that the bound ligand
would protect the RNA from cleavage by RNase A, resulting in increased protection upon an
increase in ligand concentration.
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As seen in Figure 3.7, increasing the concentration of DHR23 from 5 to 100 µM resulted
in protection of nucleotides A1492, A1493, and G1494. This result indicates that the binding site
of DHR23 is in the internal bulge region of the A-site RNA.

5'
G
G
C
G
U o
C
1408 A

3'
C
C
G
C
U
G * 1494
A *1493

A *1492
C G
A U
C G
C G
U
G
U C

Figure 3.7: Enzymatic footprinting analysis of DHR23/A-site RNA complex is shown. On the left,
an autoradiogram of the 20% denaturing polyacrylamide gel reveals RNase A cleavage sites on
3'-32P-labeled A-site RNA. Lane 1: RNA control; lane 2: alkaline hydrolysis ladder; lanes 3–5 A, U,
G chemical sequencing reactions, respectively; lane 6: RNase A cleavage in the absence of
DHR23; lanes 7–10 RNase A cleavage in the presence of 5 to 100 µM of DHR23. The A-site RNA
model is shown on the right, with stars (*) indicating the residues protected by DHR23. The
filled circles ( ) represents cleavage sites corresponding to the uridines in the hairpin loop.
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The bands that were protected from RNase A cleavage, A1492, A1493, and G1494, were
quantified and binding curves of fraction bound vs. ligand concentration
concentration were generated and
fitted to Equation 1 to obtain dissociation constants. The fraction bound was calculated by
dividing the intensity of the bands corresponding to A1492, A1493, or G1494 by the total
intensities of all bands in the lane. The bands in the lane in which no DHR23 was added (lane 6,
Figure 3.7)) represent 0% protection; hence, the bands in the other lanes were normalized
accordingly. The dissociation constants
c
obtained were: 21 ± 10 µM, 11 ± 3 µM, and 27 ± 8 µM
for A1492, A1493, and G1494,
G1494 respectively. The average Kd was 19.6 ± 8 µM,
µ which is consistent
with ESI-MS data for DHR23, will be discussed in the next chapter. The error of the individual Kd
values
lues is the error of the fit and the error of the average Kd value is the standard deviation of
the three different Kd values.

Figure 3.8:: Binding curves and dissociation constants generated from the RNase A footprinting
data are shown. The data was fit to a 1:1 binding model using Equation 1.
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RNase A is reported to specifically catalyze cleavage of the 3′ end of single-stranded
pyrimidines;231 however, it can be seen in Figure 3.7 that RNase A catalyzed the cleavage of
A1492, A1493, and G1494 in addition to the uridines present in the loop of the A-site RNA,
highlighted with black dots in Figure 3.7. This seemed surprising at first; however, Libonati and
other groups have shown that RNase A is able to catalyze the cleavage of poly-adenine
ribonucleotide, though the rate is 103 -104 less than that of poly-uridine.232-233 The preference of
RNase A for pyrimidine bases is reported to be due to specific hydrogen bonding that occurs
between the pyrimidine bases and the amino acid threonine 45, present in the active site of
RNase A. This hydrogen bond interaction is sterically excluded for purine bases;232 however, the
fact that RNase A is able to catalyze the cleavage of poly-adenine nucleotides at a slower rate
indicates that its specificity is not very stringent. The internal bulge of the A-site RNA is a
dynamic region, and therefore it could be adopting a conformation that allows A1492, A1493
and G1494 to be accommodated in the active site of RNase A. This could explain the unusual
cleavage pattern of RNase A observed in this assay.
To verify if the protection observed with DHR23 was not due to inhibition of the enzyme
by DHR23, control experiments were performed with paromomycin, chloramphenicol, and
varying salt concentrations. The results are shown in Figure 3.9. Chloramphenicol was chosen
as a negative control because it is a potent RNA binder, but it is not known to bind to the A
site.100,

234

Consequently, no protection was observed with increasing concentrations of

chloramphenicol (Figure 3.9, lanes 5-8). RNase A cleavage in the presence of increasing
concentrations of paromomycin on the other hand resulted in protection of nucleotides A1493
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and G1494 (Figure 3.9, lanes 10-12). This result is similar to what was observed with DHR23,
and consistent with previous competition experiments in which DHR23 was found to bind to a
similar region as paromomycin.201

Figure 3.9: Enzymatic footprinting analyses of chloramphenicol/A-site RNA complex,
paromomycin/A-site RNA, and A-site RNA under varying NaCl concentrations are shown. The
autoradiogram of the 20% denaturing polyacrylamide gel reveals RNase A cleavage sites on 3'32
P-labeled A-site RNA: lane 1: RNA control; lane 2 and 3: A, U, chemical sequencing reactions,
respectively; lane 4: RNase A cleavage in the absence of chloramphenicol; lanes 5–8: RNase A
cleavage in the presence of 5 to 100 µM of chloramphenicol; lane 9: RNase A cleavage in the
absence of paromomycin; lanes 10–12: RNase A cleavage in the presence of 5 to 60 µM of
paromomycin; lanes 13-15: RNase A cleavage in the presence of additional 15-60 mM NaCl.
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RNase A is cationic at physiological pH.235 Coulombic interactions between the cationic
side chains of RNase A and its substrate are crucial for substrate binding. As result, the activity
of RNase A is inhibited at high salt concentrations.236 To verify if the protection seen with
cationic DHR23 was not due to inhibition of the enzyme, a control experiment was run in the
presence of 5 – 60 mM NaCl. Lane 13 in Figure 3.9 shows RNase A cleavage of A-site RNA in
identical buffer used for the DHR23 footprinting experiments, but with additional 15 mM NaCl.
When the salt concentration was increased to 30 mM, an increase in enzymatic activity was
observed (Figure 3.9, lane 14). When the salt concentration was increased to 60 mM a
reduction of RNase A activity was observed (Figure 3.9 lane 15), but not to the level of
protection seen with DHR23. Moreover, the salt concentration in lane 15 was 600-fold greater
than the amount of DHR23 added. These results confirm that in spite of the unusual cleavage
pattern of RNase A observed in the footprinting assay, the protection bands observed were
caused by the protection of the RNA by DHR23. After determining that DHR23 binds to a similar
site on the A-site RNA as paromomycin, the next objective was to investigate if DHR23 is able to
cause conformational changes in A1492 and A1493, as observed with paromomycin.6, 85, 163

3.4.3 Mode of Binding of DHR23
Studies have shown that aminoglycosides such as paromomycin exhibit antibacterial
activity by binding to the internal bulge region of the aminoacyltransfer center of the 16 S rRNA
and stabilizing a flipped-out conformation of A1492 and A1493.95, 207, 237 This conformational
change leads to the stabilization of non-cognate aminoacyl-tRNA, thereby compromising the
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fidelity of protein synthesis. The objective was to use dimethylsulfate (DMS) to probe the
conformation of A1492 and A1493 after incubation with DHR23. The extent of DMS
modification of A1492 and A1493 would depend on their accessibility (flipped out or stacked in
the helix). A primer-extension assay was used to detect DMS modified adenines. The reaction
mechanism of DMS was discussed in Chapter 2. Initially the assay was validated by using
paromomycin as a positive control. The results are shown in Figure 3.10.

A)

B)

Figure 3.10: A) Autoradiogram of a 10% denaturing polyacrylamide gel. The lanes on the left
show primer extension products of the 16 S RNA and U, A, C, G dideoxy sequencing. The lanes
1-4 on the right show primer extension products in the absence of DMS, and DMS reactions in
the presence of 0, 5, 50, and 100 µM, respectively, of paromomycin. B) Band quantification
results for A1492 and A1493 are shown. The band intensities of A1492 and A1493 were
normalized to the total intensities of all bands in each lane.
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In the presence of increasing concentrations of paromomycin, approximately two-fold
enhancement of DMS reactivity is observed at A1492 and A1493 (Figure 3.10). This result is
consistent with literature reports in which binding of paromomycin to the A site leads to
stabilization of the flipped out conformation of A1492 an A1493 resulting in increased reactivity
with DMS.87, 95
In the next experiment, the DMS assay was repeated with DHR23. Binding of DHR23 to
the 16 S rRNA did not lead to increased reactivity of A1492 and A1493 with DMS as observed
with its parent compound paromomycin (Figure 3.11). In contrast, DHR23 seemed to cause
protection. In the presence of increasing concentrations of DHR23, there was an approximate
two-fold decrease in DMS reactivity at A1492 and A1493, suggesting that DHR23 stabilized the
stacked-in conformation of these nucleotides. Previous reports indicate that in the absence of
aminoglycosides, A1492 and A1493 sample both the stacked in and flipped out
conformations.238 In contrast, the presence of aminoglycosides such as paromomycin, causes
nucleotides A1492 and A1493 to flip out of the helix.6,

238

Also molecular dynamics data

provided evidence that the two nucleotides are flipped out simultaneously,238 but interestingly
a crystal structure of the ribosome termination complex showed that upon binding of release
factor 1, A1493 remained stacked in the helix; however, A1494 was flipped out in order to
accommodate the release factor.239 The above examples go to show that the A site is very
dynamic and can adopt different conformations in the presence of different molecules;
therefore, the stabilization of the stacked-in conformation of the two bases by DHR23 is not
surprising. However, this result implies that even though the RNase A footprinting data
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localized the binding site of both DHR23 and paromomycin to the internal bulge region of the
A-site RNA, the specific contacts made between the RNA and the two ligands are different. This
difference may influence the A-site RNA to adopt different conformations in the presence of
DHR23 or paromomycin.

A)

B)

Figure 3.11: Autoradiogram of a 10% denaturing polyacrylamide gel. The lanes on the left show
primer extension products of the 16 S RNA and U, A, C, G dideoxy sequencing. The lanes on the
right show primer extension products in the absence of DMS, and DMS reactions in the
presence of 0, 5, 30, 60, and 100 µM, respectively of DHR23. B) Band quantification results for
A1492 and A1493 are shown. The band intensities of A1492 and A1493 were normalized to the
total intensities of all bands in each lane.
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In the future design of aminoglycoside analogues, it would be prudent to utilize
molecular modeling to select side chains or functionalities that mimic the contacts made
between paromomycin and the RNA. Future efforts to improve the efficacy of DHR23 include
coupling DHR23 with a peptide (HPVHHYQ) known to cause base flipping of A1492 and
A1493.169 Our hope is that the hybrid molecule will adopt the specificity of DHR23 and the
efficacy of HPVHHYQ.
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CHAPTER 4
A MODIFIED FLUORESCENT INTERCALATOR DISPLACEMENT ASSAY FOR
RNA LIGAND DISCOVERY*
4.1

Abstract
Fluorescent intercalator displacement (FID) is a convenient and practical tool for

identifying new nucleic-acid-binding ligands. The success of FID is based on the fact that it can
be fashioned into a versatile screening assay for assessing the relative binding affinities of
compounds to nucleic acids. FID is a tagless approach; the target RNAs and the ligands or small
molecules under investigation do not have to be modified in order to be examined. In this
study, a modified FID assay for screening RNA-binding ligands was established using 3-methyl-2((1-(3-(trimethylammonio)propyl)-4-quinolinylidene)methyl)benzothiazolium (TO-PRO) as the
fluorescent indicator. Electrospray ionization mass spectrometry (ESI-MS) results provide direct
evidence that correlates the reduction in fluorescence intensity observed in the FID assay with
displacement of the dye molecule from RNA. The assay was successfully applied to screen a
variety of RNA-binding ligands with a set of small hairpin RNAs. Ligands that bind with
moderate affinity to the chosen RNA constructs (A-site, TAR, h31, and H69) were identified.

* The results presented in this chapter have been published.166
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4.2

Introduction
Developing new antibiotics requires a detailed understanding and characterization of

drug-RNA interactions. A significant challenge, however, is the development of systems for
efficient screening and discovery of ligands of interest for new RNA targets. Thus, a relatively
simple and high-throughput method such as fluorescent intercalator displacement (FID)1 240-241
for RNA applications would be very useful in the drug-discovery process. FID has become an
increasingly important tool for identifying new nucleic-acid-binding ligands. Its success is based
on the fact that it can be fashioned into a versatile high-throughput assay that can be used to
assess the relative binding affinities of compounds to nucleic acids in a relatively simple
manner, requiring only a moderate level of specialized expertise. FID has been used successfully
to identify and establish relative binding selectivities and affinities, as well as distinguish binding
modes for a variety of DNA-binding ligands.240-244 More recently, work in the laboratories of
Beal, Hergenrother, and Nakatani has shown that FID is useful for ranking and determining
selectivity of RNA-binding ligands.245-247 FID is becoming an increasingly attractive method
because it is a tagless approach; neither the RNA nor the small molecule under investigation are
modified. A dye molecule is employed, which has a greater fluorescence intensity when
intercalated (or bound) to the nucleic acid than when free in solution.240-241, 244-245 The FID assay
is based on the model in which a fluorescent probe is bound to RNA and displaced by a ligand,
leading to a reduction in fluorescence intensity (Figure 4.1). Although the traditional assay
involved intercalation of the dye molecule into DNA, the mode of binding to RNA may actually
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differ. Nonetheless, the extent of decrease in fluorescence is still proportional to the affinity of
the ligand for the RNA.

Figure 4.1: A dipiction of the displacement of a fluorescent indicator from A-site RNA by
promomycin examined by ESI-MS. The Figure was generated using coordinates from the PDB
file 1J7T.207

In this study, a modified FID method for screening RNA-binding ligands was established,
and electrospray ionization mass spectrometry (ESI-MS) was used to investigate its mechanism
(Figure 4.1). ESI-MS is a soft ionization process that was first used to detect non-covalent
interactions in 1991.180 Since then, ESI-MS has been extended to the study of non-covalent
interactions between nucleic acids and ligands as a screening tool for drug discovery.181-182 ESIMS has been successful due to the fact that it is a powerful and reliable method that can be
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used to determine stoichiometry, relative binding affinities with multiple ligands or targets, and
equilibrium binding constants in one set of experiments.182-183, 248-249 In traditional spectroscopic
methods, the bound concentration of ligand has to be relatively high in order for its
contribution to be detected, and multiple stoichiometries complicate the analysis. ESI-MS on
the other hand allows for examination of multiple stoichiometry complexes even at very low
abundance.183 Unfortunately, ESI-MS is limited to non-physiological buffers due to cationic
complexation with nucleic acids.250-251 ESI-MS is nevertheless a powerful tool that can be used
to elucidate the mechanism of FID and verify relative binding affinities obtained from this
method.
The traditional FID assays employed ethidium bromide or thiazole orange as dyes;240-242,
245

however, these dyes were either not suitable for RNA FID and/or ESI-MS assays, or not

compatible with certain types of ligands. In this study, the binding of a range of ligands from
aminoglycosides to peptides was examined by FID using an alternative dye, namely 3-methyl-2((1-(3-(trimethylammonio)propyl)-4-quinolinylidene)methyl)benzothiazolium (TO-PRO), and a
variety of bacterial and viral RNA targets (A-site RNA and helix 31 (h31) of 16 S rRNA, helix 69
(H69) of 23 S rRNA, and TAR of HIV-1 RNA).
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4.3

Materials and Methods

4.3.1 RNA Preparation
The RNA hairpins with the following sequences were purchased from Dharmacon
Research Inc. (Lafayette, CO):
5′-GGCGUCACACCUUCGGGUGAAGUCGCC-3′ (A-site RNA),
5′-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3′ (TAR RNA),
5′-GUUCGAUGCAACGCGAAC-3′ (h31), and
5′- GGCCGAψACm3ψAψAACGGUC-3′ (H69), in which ψ is pseudouridine and m3ψ is 3methylpseudouridine.
The RNAs were deprotected and purified as previously described in Chapter 3. The
concentration of RNAs were determined using Beer’s law with the following single-stranded
extinction coefficients: ε260 nm of 253,390 M-1cm-1 for A-site RNA hairpin, 268,900 M-1cm-1 for
TAR RNA, 176,900 M-1cm-1 for h31, and 189,400 M-1cm-1 for H69.224

4.3.2 Ligands
TO-PRO was purchased from Invitrogen (Carlsbad, CA). Paromomycin, neomycin and
chloramphenicol were purchased from Sigma Aldrich (St. Louis MO). Tat peptide and KkN were
purchased from Bachem (Torrance CA). CR1119 was obtained from the lab of Dr. Mark Spaller
(Dartmouth Medical School). Single-ring aminoglycoside analogues were obtained from
Shahriar Mobashery and Dusan Hesek (University of Notre Dame).
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4.3.3 FID Assay
All fluorescence readings were taken on a Cary Eclipse Spectrophotometer (Varian Inc.,
Walnut Creek, CA). Typically, 2 µM of RNA was incubated with 2 µM of TO-PRO in 150 mM
ammonium acetate buffer, pH 7, or 100 mM KCl and 20 mM Tris-Cl, pH 7, for 5 minutes. The
initial fluorescence reading was taken and the appropriate concentration of drug was then
added and mixed thoroughly and allowed to equilibrate for another 5 minutes. Five scans per
sample were taken with an excitation wavelength of 512 nm and emission wavelength of 533
nm. The level of fluorescence change (either enhancement or quenching) was determined and
converted to a percent change in fluorescence using the formula (F1/F0)*100, where F0 is the
initial fluorescence of dye bound to RNA before the addition of drug and F1 is the fluorescence
after addition of drug.

4.3.4 Electrospray Ionization Mass Spectrometry (ESI-MS)
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on a
Quattro LC tandem quadrupole mass spectrometer equipped with electrospray ionization in the
negative ion mode (Micromass, Manchester, UK). The tuning parameters, sample preparation,
data processing and fraction bound determination were discussed previously in Chapters 2 and
3. In these studies, the mass of the compounds were small compared to that of the RNA target
(i.e., <10%). Based on literature reports, an assumption was made in these studies that the
binding of ligand to the RNA does not alter the ionization efficiency of the complex.252-254
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Therefore, a correction factor for different ionization efficiencies of the free RNA and RNA
complexes was not used.184
For competition experiments, the RNA and dye solution were incubated for 5 minutes
after which the appropriate drug was added and incubated for another 5 minutes before
injection. The final concentrations of RNA and dye were 1 µM.

4.4

Results and Discussion

4.4.1 TO-PRO Association with the A-site RNA
A series of commercial dye molecules was screened for one that had ideal fluorescent
changes in the presence of RNA and no detectable fluorescence in the absence of RNA. A
common staining dye referred to as TO-PRO (3-methyl-2-((1-(3-(trimethylammonio)propyl)4quinolinylidene)methyl)benzothiazolium) (Figure 4.2) has essentially no fluorescence in the
unbound form in buffer; however, it has fluorescence enhancement of approximately 400-fold
when bound to A-site RNA. The A-site RNA is the aminoacyl-tRNA site of the decoding region of
bacterial 16 S rRNA, and a known antibiotic target site for aminoglycosides.6, 89, 206 A series of
titrations were performed with TO-PRO and the A-site RNA construct (Figure 4.2). The
intersection of the pre- and post-saturation data points for fluorescence titrations indicate that
TO-PRO associates with the A-site RNA with a stoichiometry of one (Figure 4.3A). Similarly, by
measuring the fluorescence as a function of the molar fraction of TO-PRO, a Job plot of TO-PRO
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binding to the A-site RNA was generated.255-256 The two straight lines intersected at a mole
fraction of 0.52, which indicates the presence of a 1:1 complex (Figure 4.3B).

Figure 4.2: The RNA constructs and dye indicator (TO-PRO) used in this study are shown.

A)

B)

Figure 4.3: A) Fluorescence titration data of the A-site RNA (3 µM) with TO-PRO is shown. B) A
Job plot of TO-PRO binding to the A-site RNA (3 µM) is given (buffer conditions were 100 mM
KCl, 20 mM Tris, pH 7).
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4.4.2 FID Experiments with Paromomycin and A-site RNA
Paromomycin, an aminoglycoside that is known to bind to the A-site RNA,6, 87, 203, 257 was
titrated against 2 µM of the A-site construct bound to 2 µM TO-PRO. The level of fluorescence
change (either enhancement or quenching) was determined and converted to a percent change
in fluorescence (see Materials and Methods). The results are shown in Figure 4.4. Paromomycin
was able to displace pre-bound TO-PRO from the A-site RNA. Upon addition of 31 µM of
paromomycin, the fluorescence intensity of TO-PRO was reduced to less than 30%. The buffer
conditions used were 150 mM ammonium acetate, pH 7. These conditions were chosen to
match the ESI-MS conditions for data comparison purposes. Binding experiments using A-site
RNA and paromomycin were performed in 20 mM Tris, 100 mM KCl, pH 7, and similar results
were obtained. All results shown are the average of three experiments.

Relative Fluorescence (%)
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dye + RNA 2 μM paro 10 μM paro 19 μM paro 31 μM paro

Figure 4.4: FID assay results with paromomycin are shown. Equimolar concentrations of A-site
RNA and TO-PRO dye (1 μM) were pre-bound in buffer (150 mM ammonium acetate, pH 7)
prior to paromomycin addition. An average of three separate experiments is shown.
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4.4.3 FID Mechanism Examined by ESI-MS
To determine if the change in fluorescence observed was due to displacement of TOPRO by paromomycin, ESI-MS was utilized. There could be several outcomes when dye (TOPRO) bound to RNA is treated with various RNA-binding ligands (summarized in Figure 4.5). One
possibility is that the ligand may compete for the same binding site as the dye, thereby
displacing the dye from the RNA, leading to a decrease in fluorescence intensity (1).
Alternatively, the ligand may bind to a different part of the RNA, in which case fluorescence
intensity is unchanged (2), or the ligand may interact with the dye leading to quenching of
fluorescence (3). Some ligands may not have affinity for the RNA; in this case, the fluorescence
value will be unchanged (4).

Figure 4.5: Four possible outcomes of the FID process are depicted. Refer to text for a
description of the process.
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FID is based on a model in which displacement of a fluorescent dye molecule from the
host or target results in a decrease of fluorescence intensity.240-243 In the ESI-MS experiment,
we sought evidence to support this model. Competition assays with ESI-MS allows for analysis
of the FID mechanism. ESI-MS is useful in this case because the stoichiometry of ligands to RNA
can be determined. By monitoring a titration of paromomycin into 1 µM of 1:1 A-site
hairpin:TO-PRO complex with ESI-MS, it can be observed that with increasing concentrations of
paromomycin, the amount of RNA/TO-PRO complex diminishes and the RNA/paromomycin
complex increases (Figure 4.6). This result indicates competition between the TO-PRO dye and
paromomycin for binding to the RNA hairpin. The appearance of a peak representing a complex
of RNA/paromomycin/TO-PRO indicates that paromomycin and TO-PRO have additional noncompeting binding sites on the RNA hairpin. This result is not surprising since paromomycin is
known to be a promiscuous RNA binder.258-259
The extent of TO-PRO displacement by binding of paromomycin in ESI-MS was
quantified and the results are shown in Figure 4.6. At 15 µM paromomycin, only a negligible
amount of TO-PRO remains bound to the RNA. These data are consistent with a displacement
model and corresponding decrease in fluorescence intensity of TO-PRO as it is dissociated from
the RNA target (as shown in Figure 4.5, example 1).
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[paro]
µM
0
1
3
6
10
15

fraction bound
(TO-PRO)
0.29
0.25
0.20
0.19
0.13
0.04

Figure 4.6: ESI-MS spectra showing a titration of paromomycin (0–15 µM) into equimolar
concentrations of A-site RNA and TO-PRO complex (1 µM). Buffer conditions are 150 mM
ammonium acetate, pH 7. The insert table shows quantification of the ESI-MS peak areas of the
TO-PRO:A-site RNA complex after titration with 0–15 µM of paromomycin.

4.4.4 A-Site RNA and Chloramphenicol
Chloramphenicol is a potent antibiotic that binds to 23 S rRNA in the petidyl-transferase
center of the ribosome and inhibits protein synthesis.260-262 Chloramphenicol was chosen to
serve as negative control because it is a strong RNA binder, but is not known to bind to the A-
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site RNA. A titration of chloramphenicol into the A-site/TO-PRO complex showed no significant
change in fluorescence, even after addition of 31 µM of Chloramphenicol (Figure 4.7) In
contrast, more than 70% reduction in fluorescence was observed in the case of paromomycin
(Figure 4.4).

Relative Fluorescence (%)
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Figure 4.7: FID assay results with chloramphenicol are given. Equimolar concentrations of A-site
RNA and TO-PRO (1 μM) were pre-bound in buffer (150 mM ammonium acetate, pH 7) prior to
chloramphenicol addition. An average of three separate experiments is shown.

The ESI-MS data also confirm the FID result with chloramphenicol. There was no
significant change in peak areas of the RNA:TO-PRO complex upon addition of 100 µM of
chloramphenicol (Figure 4.8). There was no observable peak representing the binding of
chloramphenicol to the A-site RNA, which was expected at an m/z value of 1790. A control scan
confirmed that at 40 µM of chloramphenicol, there is a high concentration of chloramphenicol
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in the injected solution as compared to RNA (inset of Figure 4.8). This result would be
consistent with example 4 in Figure 4.5.

[chlo]
µM
0
5
40
100

fraction bound
(TO-PRO)a
0.23
0.26
0.29
0.26

Figure 4.8: ESI-MS spectra show a titration of chloramphenicol into equimolar concentrations of
A-site RNA and TO-PRO complex (1 µM). Buffer conditions are 150 mM ammonium acetate, pH
7. Insert shows the relative concentrations free RNA and free chloramphenicol after 40 µM of
chloramphenicol was titrated into the pre-bound A-site RNA and TO-PRO complex. The insert
table shows quantification of the ESI-MS peak areas of TO-PRO:A-site RNA complex after
titration with 0–100 µM of chloramphenicol.
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4.4.5 TAR RNA and Tat
Human immunodeficiency virus type 1 (HIV-1) gene expression is controlled by binding
of a viral regulatory protein, known as the trans-activator of transcription (Tat), to its RNA
target, the trans-activation responsive region (TAR).118-120 This Tat-TAR interaction is crucial for
the successful replication of HIV-1.118-120 Consequently, disruption of this Tat-TAR interaction
has been a good prospect for developing new HIV therapies.263-265 Studies have identified the
minimal motifs for the specific interaction of Tat-TAR to be the 9mer basic amino-acid region of
Tat (residues 49-57) and the UCU bulge of the TAR RNA (Figure 4.2 and Figure 4.11).263-265 This
well-characterized Tat-TAR system was used in the modified FID assay.
FID and ESI-MS experiments were both carried out using the Tat-TAR system. The FID
results from the Tat-TAR system show a similar trend as observed with the Asite/aminoglycoside system. Upon addition of 31 µM Tat peptide, a 70% decrease in
fluorescence is observed (Figure 4.9). The reduction in fluorescence was confirmed by using
ESI-MS to be due to the displacement of pre-bound TO-PRO from the TAR RNA (Figure 4.10).
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Figure 4.9: FID assay of Tat peptide utilizing pre-bound
pre bound equimolar concentrations of TAR RNA
and TO-PRO (1 μM each).. Buffer conditions were 150 mM ammonium acetate, pH 7.
7 The data
shown is an average of three separate experiments.

[Tat]
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fraction
bound
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0.42
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Figure 4.10: ESI-MS
MS spectra showing a titration of Tat peptide into equimolar concentrations of
TAR RNA and TO-PRO
PRO complex (1 µM). Buffer conditions are 150 mM ammonium acetate, pH 7.
The insert table shows quantification
uantification of the ESI
ESI-MS peak areas of TO-PRO:A
PRO:A-site RNA complex
after titration with 0–25 µM
M Tat peptide.
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4.4.6 FID Screening Results with RNA Constructs and Ligands
As shown in the previous sections, two well-studied RNAs and known ligands were used
to validate the modified FID assay with TO-PRO, namely the Tat-TAR system 119, 266-267 and the Asite RNA-aminoglycoside (paromomycin) system.92,

268-270

Since the binding sites of

paromomycin and Tat are well characterized, these results suggest that the TO-PRO dye
molecule associates with the RNAs in the secondary structure elements, namely the nucleotide
bulge regions. Our next goal was to test new ligands against the A-site RNA and TAR RNA, and
carry out FID with previously untested RNA model systems, namely helix 69 (H69) and helix 31
(h31). These RNAs represent functionally important sites of the bacterial ribosome. H69, from
the large subunit of the ribosome, is located in the intersubunit bridge B2a region and makes
important contacts with the small ribosomal subunit, A- and P-site bound tRNAs, as well as
translation factors.103-104 This RNA contains two modified nucleotides, pseuduridine (Ψ) and 3methylpseudouridine (m3Ψ), which can be inserted into the RNA model systems by using
synthetic approaches.271 The small subunit hairpin h31 is located in the 970-loop region of 16S
rRNA. Helix 31 serves as a promising drug target because it is located near the P-site (peptidyltRNA site) and is proposed to be involved in the decoding process.105-107 This region is also
modified, but we chose the unmodified variant for this study. The h31 and H69 RNAs contain
secondary structure elements that differ from the A-site RNA and TAR RNA, such as larger loop
regions and nucleotide mismatches.
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The FID assay was used to identify ligands for the four RNA constructs shown in Figure
4.2. The structures of the ligands employed are shown in Figure 4.11. Among the compounds
screened, the cationic aminoglycosides, paromomycin and neomycin, are known to target the
A-site RNA.92 Simplified aminoglycoside, or single-ring derivatives of paromomycin, referred to
as DHR23, DHR36, DHR37, DHR42, and DHR51, were also screened. These compounds were
designed with the goal of retaining their RNA-binding ability, but reducing their affinity for
resistance enzymes, which are known to modify aminoglycosides and reduce their association
with RNA.205, 272 KkN is a tri-peptide containing D-lysine (k) that was selected by Hwang and
coworkers to target TAR RNA.273 CR1119 is a peptide-based compound that contains potential
intercalating groups for nucleic-acid binding.

Figure 4.11: The RNA binding ligands used in this study are shown.

99

The results of the screen reveal that FID is a promising method for rRNA or TAR RNA
ligand discovery. The assay was suitable for RNAs with different sequences and secondary
structures, as well as modified nucleotides. Perhaps not surprising, the cationic RNA ligands,
paromomycin, neomycin, and Tat, show binding to all four constructs, the A-site, h31, H69, and
TAR RNAs (Figure 4.12).

Figure 4.12: FID screening results obtained for the different RNA constructs upon addition of
ligand concentrations ranging from 0–100 µM: A) A-site RNA, B) H69 RNA, C) h31 RNA, and D)
TAR RNA (buffer conditions are 20 mM Tris, 100 mM KCl, pH 7).

As expected chloramphenicol, which is known to be specific for the peptide exit tunnel
in the 50S rRNA,261-262 had only slight affinity for the RNA constructs. DHR23, a single-ring
analogue of paromomycin, had a slight preference for the A-site RNA and TAR RNA, and CR1119
had a preference for h31 (Figure 4.12). In contrast, DHR51, which is similar in structure to
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DHR23 but contains tert-butyloxycarbonyl (BOC) groups at the amine positions (Figure 4.11),
had reduced affinity to all of the RNA constructs.
The FID results for paromomycin and DHR23 with H69 and A-site RNA were further
evaluated by ESI-MS. Dissociation constants obtained from ESI-MS experiments show that
DHR23 has a higher affinity for A-site RNA as compared to H69 (Kd = 19 and 42 µM,
respectively). Paromomycin also demonstrated a higher affinity for the A-site RNA as compared
to H69 (Kd = 1.3 and 21 µM, respectively). These dissociation constants are therefore consistent
with the FID data (Table 4.1).

Table 4.1: Comparison of the FID results and dissociation constants for DHR23 and
paromomycin binding to H69 and A-site RNA.
DHR23

A-site
RNA
H69

paromomycin

fluorescence
(%)

Kd
(µM)a

fluorescence
(%)

Kd
(µM)a

54
83

19
42

14
36

1.3
21

In summary, a modified FID assay for RNA applications has been developed and the ESIMS data provide molecular evidence that correlates the reduction in fluorescence observed in
the FID assay with the displacement of the TO-PRO dye molecule from RNA. FID with TO-PRO is
an appropriate method for obtaining relative binding affinities of a variety of ligands to RNA,
including amino sugars, peptides, and planar aromatic compounds. The FID assay will be
amenable to high-throughput screening because it is a sensitive, fluorescence-based method
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that can be done on a 96- or 384-well plate format. The system is compatible with cationic
buffer components, including Mg2+, Na+, and K+, which are not suitable for ESI-MS screening.
The moderate selectivity of DHR23 for the A-site and TAR RNAs relative to the ribosomal targets
H69 and h31 is encouraging. In contrast, the aromatic compound CR1119 has a slight
preference for h31, which contains a six-nucleotide loop and mismatch at the loop-closing base
pair. These results suggest that generation of compounds based on these simplified structures
in combination with FID screening may lead to selective reagents for RNA internal bulges, loops,
mismatches, or other unique secondary structure elements.
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CHAPTER 5
SPECIFICITY OF DHR23
5.1

Abstract
Aminoglycosides are known to be promiscuous ligands. Their ability to bind to a wide

variety of RNAs has been exploited for new applications in HIV and genetic disease therapy.
Investigating the specificity of aminoglycosides is worthwhile in order to understand their mode
of action, and also to identify new drug targets.
In this study, the specificity of DHR23 (a single-ring analogue) and its parent compound
paromomycin were tested for binding to a variety of RNA models using electrospray ionization
mass spectrometry (ESI-MS). The results show that DHR23 has preferred binding to structured
RNA as compared to ssRNA, as well as a modest preference for the A-site RNA. The absence of
the other three rings of paromomycin reduced the affinity of DHR23 for the A site RNA by about
10-fold. Even with the reduction in affinity, DHR23 was still able to retain a slight level of
selectivity for the A-site RNA.

5.2

Introduction
Aminoglycosides are a group of antibiotics that have been used successfully against

many disease-causing bacteria.111-112 They work by binding to the highly conserved region of
the ribosome (A site) and inhibit protein synthesis.274-275 In spite of its success, aminoglycoside
therapy is associated with severe side effects, which may be due to the binding of
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aminoglycosides to other targets besides the A site.276 The promiscuity of aminoglycosides is
not a new phenomenon; they have been reported bind to a variety of RNA structures, including
TAR RNA,277 mRNA,278 and the hammerhead ribozyme.279 Their lack of selectivity has been
attributed to their electrostatically driven binding mode and conformational flexibility.280-281
However, some studies have shown that aminoglycosides do have a strong preference for
structured RNA and A-form RNA.282 Also, the flexibility around their glycosidic bonds provides
an advantage to target conformationally flexible RNAs such as the A site.237, 283-285 Therefore, in
spite of the fact that aminoglycosides are recognized for their promiscuity, studies suggest that
there may be certain sequence-structure and conformation-dependent elements in their
recognition of their target RNAs.87, 282-283
In this study, the specificity of DHR23; a single-ring aminoglycoside analogue discussed
in Chapter 3 and its parent compound paromomycin were tested against a variety of RNA
models using electrospray ionization mass spectrometry (ESI-MS). Among the RNA models used
are an A-site RNA duplex and the A-site RNA hairpin model, which has an artificial GNRA
tetraloop added to increase stability (Figure 5.1).207 GNRA teteraloops are very common
structural motifs found in rRNA.286-287 They serve as protein binding sites and participate in
tertiary structure interactions that contribute to the formation of proper three-dimensional
structures.286 There have been several reports of aminoglycosides binding to hairpin loops.288
The reason for choosing this pair (duplex and hairpin A-site models) is to determine whether
the affinity of the ligands for the A-site RNA is affected by the artificial tetraloop in the A-site
RNA hairpin model. Furthermore, helix 69 (H69) of the large ribosomal subunit and helix 31
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(h31) of the small ribosomal subunit represent functionally important sites of the bacterial
ribosome. H69 is located in the inter-subunit bridge, B2a, and makes important contacts with
the small ribosomal subunit, A- and P-site bound tRNAs, as well as translation factors.103-104
Helix 31 is the 970-loop region located in the 16 S rRNA. It serves as a promising drug target
because it is located near the P site and it is proposed to be involved in the decoding
process.105-107 Other RNA models used the bacterial A-site mutant RNA, human A-site RNA, and
a 16-nucleotide single-stranded RNA.

5.4 Experimental
5.4.1 RNA Preparation
The RNA hairpins with the following sequences were purchased from Dharmacon
Research Inc. (Lafayette, CO):
5′-GGCGUCGUACUUCGGUAAAAGUCGCC -3′ (human A-site)
5′-CAGCGUCACACCACCC -3′ (A-strand),
5′- CAGCGUCAUCACCACCC-3′
5′-GGUGGUGAAGUCGUGG -3′ (A-site duplex), and
5′-CAGCGUCAUCACCACCC -3′
5′-GGUGGUGAAGUCGCUGG -3′ (A-site mutant),
Information for the other RNAs used in this study was provided in Chapter 4. The RNAs were
deprotected and purified as previously described in Chapter 3. The concentrations of RNAs
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were determined using Beer’s law with the following single-stranded extinction coefficients:
ε260 nm of 252,900 M-1cm-1 for human A-site, 143,300 M-1cm-1 for A-strand RNA, 316,800 M1

cm-1 for A-site duplex, and 322,000 M-1cm-1 for A-site mutant.224

5.4.2 Electrospray Ionization Mass Spectrometry (ESI-MS)
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on a
Quattro LC tandem quadrupole mass spectrometer equipped with electrospray ionization in the
negative ion mode (Micromass, Manchester, UK). The tuning parameters, sample preparation,
data processing and dissociation constant determination were discussed previously in Chapters
2 and 3.

5.3

Results and Discussion
As determined by ESI-MS, paromomycin had the same affinity for both the A-site hairpin

and the A-site duplex RNA (1.3 µM). Buffer conditions used were 150 mM ammonium acetate
pH 7 (Figure 5.1). Similarly, there was no significant difference observed between the affinity of
DHR23 for the A-site hairpin and A-site duplex RNAs (Kds were 19 µM and 20 µM, respectively;
Figure 5.1). This result suggests that the teteraloop had no significant effect on the affinity of
the two ligands for the A-site RNA.
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A)

B)

Figure 5.1: A) The chemical structures of the ligands tested for specificity are shown. B) A
summary of affinities of DHR23 and paromomycin for the different RNA constructs is given. The
conserved A-site sequence from the bacterial 16 S rRNA is highlighted in black on the A-site
hairpin, A-site duplex, and A-site mutant, and for comparison, indicated on the 18 S rRNA
construct. The nucleotides that differ from the bacterial 16 S rRNA A site are highlighted in blue
on the A-site mutant and the human A site.
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DHR23 and paromomycin were both able to discriminate between the A-site duplex
RNA and an A-site mutant RNA. As compared to the A-site RNA, the A-site mutant has a uridine
in the internal bulge region, affording base pairing between uridine and adenosine just below
the A.A mismatch (Figure 5.1). The ESI-MS spectra and binding curves as well as the RNA
structures are shown in Figures 5.2 to 5.30. This base pairing disrupts the formation of the
internal bulge, leading to reduced binding affinity of DHR23 and paromomycin to the A-site
mutant. This result suggests that the internal bulge structure is important for binding of both
paromomycin and DHR23 to the A site.
Nucleotides 1404-1407 and 1492-1497 are universally conserved in all 16 S rRNA of
bacteria (Figure 5.1A).289 The highly conserved nature of this region of the ribosome suggests
that its function is dependent on the sequence.289 Aminoglycosides preferentially target
bacterial over eukaryotic ribosomes.290 The only difference between the nucleotide sequence
of the bacterial and the eukaryotic A site internal bulge is the presence of an adenosine at
position 1408 in bacteria and a guanosine in eukaryotes (highlighted in blue on the human Asite RNA structure in Figure 5.1).289 Consequently, an A1408G mutation in E. coli confers a high
level of resistance to aminoglycosides with a 6′ NH2 (e.g., neomycin) and low level resistance to
aminoglycosides with a 6′ OH (e.g., paromomycin).197 Our data is consistent with previous
results; DHR23 and paromomycin both had a higher preference for the bacterial A-site RNA as
compared to the human A-site RNA. This result further corroborates structure,291 studies
suggesting that the binding pocket created A1408 and A1492 base pair present in the bacterial
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A site cannot be mimicked by replacement with a G1408 and A1492 base pair, such as the one
present in the human ribosomal A site.291
Aminoglycoside antibiotics have been recently reported to bind to H69;292-293 therefore,
it was not surprising that in our hands, paromomycin had moderate affinity to H69 (Kd of 21
µM). Helix 31 displayed two-fold weaker binding to paromomycin compared to helix 69. DHR23
on the other hand had weaker affinity for both H69 and h31 (47 µM and 95 µM, respectively;
(Figure 5.1). Compared to H69, h31 has a bigger hairpin loop. These two RNAs also contain
different mismatch base pairs and different modified nucleotides. Crystal structure data
indicate that neomycin binds to the stem region of H69, in the vicinity of the G1907·U1923
mismatch.293 Ring I of neomycin makes contacts with G1906, and ring II interacts with G1921
and U1923.293 This region of H69 adopts a conformation similar to that of the A-site internal
bulge. The tertiary structure of h31 on the other hand adopts a conformation completely
different from H69 and the A-site RNA (Figure 5.2). This structure may be unsuitable to provide
appropriate contacts for either paromomycin or DHR23 to bind. H69 was able to accommodate
the parent aminoglycoside more readily than the smaller derivative. Clearly rings II-IV of
paromomycin play a role in governing selectivity, and future designs of selective compounds
will have to take that into consideration. Since aminoglycosides prefer to bind to structured
RNA,282 it was not surprising that both ligands had poor affinity for the A-strand RNA (Figure
5.1).
In general, DHR23 has preferred binding to structured RNA as compared to ssRNA, as
well as a modest preference for the A-site RNA, as observed with the parent compound
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paromomycin (Figure 5.1). The absence of the other three rings in DHR23 as compared to
paromomycin, reduced its affinity for the A-site RNA by about 10-fold. Even with the 10-fold
reduction in affinity, DHR23 was still able to retain a slight level of selectivity for the A-site RNA.
These results add some credence to the hypothesis that further reduction of the neamine core
to generate A-site selective ligands is possible.

A)

B)

C)

Figure 5.2: A) NMR structure of the bacterial A-site model,87 B) crystal structure of H69,77 and C)
crystal structure of h3177 are shown. The figures were generated with PyMOL49 using the
following PDB files: 1A3M, 2WDG, and 2WDI.

110

Figure 5.3: ESI-MS spectra of A-site hairpin vs. DHR23 are shown. Buffer conditions were 150
mM ammonium acetate pH 7.
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Figure 5.4: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and the A-site hairpin RNA, and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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The errors in curves A-C (± 4 µM, ± 3 µM, and ± 5 µM) represent the error of the fit. In
other word, how well the binding model fits the data points. Since curves A-C are single
experiments a weighting value of one is given to all the data points, or all data points are
assigned the same level of importance. As a result the estimated error may not be accurate. In
curve D, the data points represent the average from the three experiments (A-C). The error bars
are generated using the standard deviation of each data point in curves A-C. The estimated
error (± 3 µM), represents how well the binding model fits the data points taking into
consideration the weighted value of each data point, based on the standard deviation of the
data point. In other words different importance is assigned to each data point based on their
standard deviation. This generates a more reliable error estimate. The error in bold letters (± 2
µM) represents the standard deviation of the three different experiments.
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Figure 5.5: ESI-MS spectra of A-site duplex vs. DHR23 are shown. Buffer conditions were 150
mM ammonium acetate pH 7.
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Figure 5.6: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and the A-site duplex RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.7: ESI-MS spectra of A-site mutant vs. DHR23 are shown. Buffer conditions were 150
mM ammonium acetate pH 7.
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Figure 5.8: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and the A-site mutant RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.9: ESI-MS spectra of human A-site vs. DHR23 are shown. Buffer conditions were 150
mM ammonium acetate pH 7.
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Figure 5.10: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and the human A-site RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.11: ESI-MS spectra of H69 vs. DHR23 are shown. Buffer conditions were 150 mM
ammonium acetate pH 7.
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Figure 5.12: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and H69 RNA and (D) the average of the three experiments ± error of fit and standard
deviation (in bold letters) are shown.
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Figure 5.13: ESI-MS spectra of h31 vs. DHR23 are shown. Buffer conditions were 150 mM
ammonium acetate pH 7.
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Figure 5.14: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and h31 RNA and (D) the average of the three experiments ± error of fit and standard
deviation (in bold letters) are shown.
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Figure 5.15: ESI-MS spectra of A-strand vs. DHR23 are shown. Buffer conditions were 150 mM
ammonium acetate pH 7.
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Figure 5.16: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and A-strand RNA and (D) the average of the three experiments are shown.
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Figure 5.17: ESI-MS spectra of A-site hairpin vs. paromomycin are shown. Buffer conditions
were 150 mM ammonium acetate pH 7.
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Figure 5.18: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and A-site hairpin RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.19: ESI-MS spectra of A-site duplex RNA vs. paromomycin are shown. Buffer conditions
were 150 mM ammonium acetate pH 7.
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Figure 5.20: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and A-site duplex RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.21: ESI-MS spectra of A-site mutant RNA vs. paromomycin are shown. Buffer
conditions were 150 mM ammonium acetate pH 7.
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Figure 5.22: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and A-site mutant RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.23: ESI-MS spectra of human A-site RNA vs. paromomycin are shown. Buffer conditions
were 150 mM ammonium acetate pH 7.
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Figure 5.24: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and human A-site RNA and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 5.25: ESI-MS spectra of H69 RNA vs. paromomycin are shown. Buffer conditions were
150 mM ammonium acetate pH 7.
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Figure 5.26: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin H69 RNA and (D) the average of the three experiments ± error of fit and standard
deviation (in bold letters) are shown.
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Figure 5.27: ESI-MS spectra of h31 RNA vs. paromomycin are shown. Buffer conditions were
150 mM ammonium acetate pH 7.
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Figure 5.28: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin h31 RNA and (D) the average of the three experiments ± error of fit and standard
deviation (in bold letters) are shown.
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Figure 5.29: ESI-MS spectra of A-strand RNA vs. paromomycin are shown. Buffer conditions
were 150 mM ammonium acetate pH 7.
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Figure 5.30: Binding curves (A-B) obtained from three different ESI-MS experiments between
paromomycin A-strand RNA and (C) the average of the three experiments are shown.
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CHAPTER 6
ROLE OF MODIFIED NUCLEOTIDES IN DRUG BINDING: TARGETING
THE RIBOSOMAL A SITE*
6.1

Abstract
The decoding region of the ribosome is a well-established drug target for a wide variety

of antibiotics. Present in the decoding region of the bacterial ribosome are modified
nucleotides that are conserved across phylogeny.

Modified nucleotides have been well

characterized for the roles they play in antibiotic sensitivity and resistance; however, the roles
that modified nucleotides play in antibiotic binding are not well understood. In this study,
antibiotic binding studies were performed with modified and unmodified decoding region
constructs using electrospray ionization mass spectrometry. Our results show that modified
nucleotides may enhance or reduce the affinity of certain antibiotics for the decoding region.

6.2

Introduction
There is a wide variety of post-transcriptionally modified nucleotides present in the

ribosome. Over 100 of these modifications have been identified in bacterial and eukaryotic
cells.46
* The synthesis of modified RNAs reported in this chapter was carried out by Santosh Mahto.

140

The modified nucleotides are thought to modulate the specific folding of the RNA in a variety of
ways, including improving base stacking,294-296 and increasing or decreasing the potential for
hydrogen bonding.297-299 There are three modifications present in the decoding region of the E.
coli ribosome; namely, m3U, m5C and m4Cm (Figure 6.1B).31, 34 Nucleotide base methylation
may increase base stacking due to its hydrophobicity, block hydrogen bonding when present at
Watson-Crick edges (such as in m3U), or cause structural changes induced by steric
hindrance.296, 298, 300 Furthermore, nucleosides with sugar methylations in the 2′-OH position
(such as in m4Cm) favor the 3′-endo sugar conformation and can block interactions at the sugar
edge.301-302
The roles that modified nucleotides play in antibiotic resistance and susceptibility have
been well documented. For example, methylation at the 2′-OH position of nucleotide A1067
located in the large ribosomal subunit of Streptomyces azureus confers resistance to the
antibiotics thiostrepton and micrococcin.303 Other base methylations such as mono and
dimethylation of A2058 in the 23 S rRNA confer resistance to three different classes of
antibiotics; monomethylation of A2058 causes a high level of resistance to lincosamides, but a
low level resistance to macrolides and streptogramin B. On the other hand, dimethylation of
this nucleotide confers a high resistance to all the three classes of the aforementioned
antibiotics.304-305 Inhibition or lack of housekeeping methylations may also lead to antibiotic
resistance as seen in the case of kasugamycin, in which loss of methylations at A1518 and
A1519 confer resistance to kasugamycin.306 The above examples underscore the importance of
investigating the impact of rRNA modifications on ligand binding and drug targeting.
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A)

B)

Figure 6.1: The E. coli rRNA constructs are shown: (A) unmodified and (B)
(B modified decoding
region. The blue
lue spheres indicate contacts made by paromomycin and green open spheres
indicate contacts made by hygromycin B.
B
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The study of RNA-ligand interactions are beneficial and an important area of research.36,
158

Some of methods used to investigate the various aspects of RNA-ligand interactions include

gel-based methods such as footprinting,307 and biophysical methods such as ITC,308 SPR,309
NMR,310 and ESI-MS.182 These methods can be used to obtain parameters such as binding
affinities, stoichiometries, kinetics, and binding sites of ligands on RNA (an overview of these
techniques was given in Chapter 1). In recent times, ESI-MS has been the method of choice
because of its speed and convenience.182, 311-312 Labeling of the analyte is not necessary, and
only a few picomoles of the sample is required for ESI-MS experiments. Also, ESI-MS provides
distinct mass signatures that can be unambiguously resolved; therefore, several competition
experiments can be performed. Binding experiments have been performed using of various
ligands and unmodified decoding region (previously).313 However, the effects of all naturally
occurring modified nucleotides on ligand binding have not been considered. In this study, ESIMS experiments were carried out using well-studied aminoglycosides, paromomycin, neomycin,
kanamycin A and hygromycin B, as well as newly discovered ligands, peptide HPVHHYQ-NH2314
and an aminoglycoside analogue DHR23 (Figure 6.2). The binding affinities of these ligands to
the modified (wild-type) and unmodified decoding region variants (Figure 6.1) were compared.
This project was done in collaboration with Santosh Mahto.
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6.3

Experimental

6.3.1 RNA Preparation
Synthesis of the modified decoding region oligonucleotides has previously been
reported.302, 315 The RNAs were purified and desalted as previously described in Chapter 3. The
concentration of RNAs were determined at 90 °C using Beer’s law with the following singlestranded extinction coefficients: ε260 nm 190,400 cm-1M-1 and 242,500 cm-1M-1 for the 5' half
(21 mer oligonucleotide) and the 3' half (24 mer oligonucleotide), respectively. The
oligonucleotides were dissolved in 1 M ammonium acetate buffer and duplex formations were
achieved by heating the RNA samples at 94 °C for 3 min and slow cooling to room temperature
in a heat block.

6.3.2 Ligands
Paromomycin, neomycin, kanamycin A, and hygromycin B were purchased from Sigma
Aldrich (St. Louis MO) and used without further purification. The aminoglycoside analogue,
DHR23, was obtained from Shahriar Mobashery (University of Notre Dame). Stock solutions of
paromomycin, neomycin, kanamycin A, hygromycin B, and DHR23 were prepared with doubledistilled water. Synthesis of the peptide HPVHHYQ-NH2 was done by A.C. Duc.314 The peptide
concentration was calculated by measuring absorbance at 280 nm and using equation
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C = A280 / (# tyr • ε tyr + # trp • ε trp) • λ in which the extinction coefficient of tyrosine (ε tyr) is 1490
cm-1M-1, the extinction coefficient of tryptophan (ε trp) is 5560 cm-1M-1, λ is the pathlength, and
#tyr and #trp are the number of tyrosine and tryptophan residues, respectively.

6.3.3 Electrospray Ionization Mass Spectrometry (ESI-MS)
Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on a
Quattro LC tandem quadrupole mass spectrometer equipped with electrospray ionization in the
negative ion mode (Micromass, Manchester, UK). The tuning parameters, sample preparation,
data processing and fraction bound determination were discussed previously in Chapters 2 and
3.

6.4

Results and Discussion
The interaction of paromomycin, neomycin, and kanamycin with the A-site RNA has

been studied extensively by different methods under various buffer conditions.95, 316-318 The Kd
values reported for aminoglycoside-RNA interactions range from 5 nM to 100 μM.6, 163, 319-320
The results from our binding studies are consistent with literature values.6, 163, 319-320 The data
show that the ligands (paromomycin, neomycin, kanamycin and HPVHHYQ) that bind to the
lower region on the A site (see Figure 6.1) have a negligible or only small preference (0.6 to 0.9fold difference) for the unmodified decoding region over the modified decoding region (Table
6.1).
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Figure 6.2: Chemical structures of the decoding region-targeting ligands are shown.

Table 6.1: Summary of the binding study results

Dissociation constant, Kd (μM)
Unmodified
Modified
a
decoding region
decoding regiona
0.7 ± 0.3
0.8 ± 0.3

Ligands
Paromomycin
Neomycin

2.0 ± 0.4

Unmod/mod
0.9

2.0 ± 0.3

1

Kanamycin A

8±1

12 ± 1

0.7

Hygromycin B

25 ± 4

15 ± 7

1.7

HPVHHYQ-NH2

31 ± 7

50 ± 7

0.6

9±2

18 ± 6

0.5

DHR23
a

Values reported are an average of three experiments ± one standard deviation
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Crystal structures and NMR solution structures reveal that paromomycin binds at G1405,
A1408, C1490, G1491, A1493, and U1495 (Figure 6.1 and Figure 6.3).95, 207, 293, 316, 321 These
residues are far from the modified nucleotides with the exception of m5C at 1407. Therefore,
m5C appears to have no contribution to the binding, perhaps due to lack of a direct contact
between the ligands (paromomycin, neomycin, kanamycin A, and HPVHHYQ) and this residue.
The other two modified nucleotides (m4Cm and m3U) are not close to the binding site.

A)

B)

Figure 6.3: The structures of: A) hygromycin B and B) paromomycin bound to the decoding
region. The modified nucleotides present in the decoding region are highlighted in blue. The
figures were generated with PyMol software322 using coordinates from PDB files 2Z4K and
1HNZ.94, 293
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Interestingly, hygromycin B slightly prefers binding to the modified decoding region,
with a Kd of 15 μM over the unmodified decoding region, with a Kd of 25 μM (Table 6.1). A
Crystal structure of hygromycin B bound to the 30 S subunit reveals that this aminoglycoside
binds to the decoding region nucleotides C1403, G1405, A1408, C1496, G1491, A1493, U1495,
and the modified nucleotide m3U1498 (Figure 6.1 and Figure 6.3A).94 In this case, the modified
nucleotide m3U1498 makes contact with hygromycin B. Thus, the modified residue appears to
play a role in enhancing the binding affinity by approximately 1.5 fold. The methylation at the
N3 position of uridine may favor stronger hydrogen bonding interactions between the O4
position of uridne and hygromycin B (through inductive effect) (Figure 6.4). Alternatively the
presence of the methyl group may affect the local conformation299 of the RNA resulting in more
favorable interactions with hygromycin B. This result is consistent with earlier findings in which
U1498C mutation leads to hygromycin resistance in Mycobacterium smegmatis.323 Mutation of
this methylated uridine to a cytidine leads abolishment of hydrogen bonding interactions
between O4 of uridine and hygromycin B, which eventually leads to resistance.

Figure 6.4: The structure of 3-methyluridine is shown.
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The peptide HPVHHYQ-NH2, selected through phage display, targets the ribosomal A
site.314 The reported Kds of the peptide range from 2 to 29 μM with a smaller unmodified RNA
construct by different methods such as ITC, footprinting, and ESI and in various buffers.314 Here,
we studied the binding affinity of the peptide HPVHHYQ-NH2 with unmodified and modified
decoding region RNAs. It has a slight preference for the unmodified (Kd = 31 μM) over the
modified decoding regions (Kd = 50 μM) (Table 6.1). Footprinting data show that the peptide
HPVHHYQ-NH2 binds to nucleotides A1492 and A1493 of the A-site loop on the smaller A-site
RNA construct.314 Its binding site is on the opposite side of the loop-modified nucleotide
m5C1407, similar to the aminoglycosides. The modification may slightly change the loop
structure. Therefore, the slight difference between the binding affinities of the modified and
unmodified decoding regions may result from slight structural changes facilitated by the
modified nucleotide m5C, which has been shown to destabilize the decoding region.315
Furthermore, the peptide was selected for binding to unmodified A-site RNA; thus it is not
surprising that it has a higher affinity for the unmodified decoding region. Paromomycin

and

kanamycin A belong to 4,5-linked and 4,6-linked aminoglycoside families, respectively.114 Even
though ring I and II of these two aminoglycoside families (neamine core) adopt similar
conformations when bound to the A site, differences exist in the interactions of the other rings
with the A site.6, 208 Since the difference in selectivity of HPVHHYQ for the modified and
unmodified decoding region (unmod/mod = 0.6, Table 6.1) is very similar to that of kanamycin,
it suggests that HPVHHYQ may have a similar binding mode as kanamycin. The data also suggest
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that only slight differences in binding modes exist between HPVHHYQ, paromomycin,
neomycin, and kanamycin A.
The aminoglycoside analogue DHR23 was found to bind to the A-site RNA with
moderate affinity. Results from Chapter 5 show that DHR23 preferentially binds to bacterial Asite RNA, having a Kd of 19 μM compared to bacterial A-site mutants, human A site, helix 69,
and helix 31, which had Kds of 34, 29, 47, and 95 μM, respectively. In this study, DHR23 shows a
two-fold reduced binding affinity toward the modified decoding region having Kds of 9 and 18
μM for the unmodified decoding region and modified decoding region, respectively (Table 6.1).
Its binding site is different from the parent aminoglycoside and might be closer to the modified
region, such that binding interactions may be affected by the presence of methylated residues.
Alternatively, slight differences in the RNA conformation due to the modified nucleotide may
impact the binding of DHR23. Similar to the data from Chapter 3, the difference in selectivity of
DHR23 for the modified and unmodified decoding region suggests that DHR23 has a different
binding mode compared to the parent aminoglycoside. Since DHR23 binds to the unmodified
RNA slightly better than the corresponding modified decoding region (wild type), resistance to
DHR23 would be less likely to occur by inhibition of housekeeping methyltransferase enzymes,
as seen in the case of kasugamycin resistance. This result also suggests that it may be prudent
to include modified nucleotide constructs (wild type) in the screening process when developing
new anti-infectives.
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6.5: Conclusions
The results from the binding experiments indicate that modified nucleotides may affect
the binding affinity of ligands. For example, hygromycin B had a slightly higher binding affinity
for the modified decoding region compared to the unmodified decoding region. On the other
hand, DHR23 had a slight preference for the unmodified decoding region. These results go to
show that modified nucleotides may play an important role in modulating the binding affinity of
ligands if they are present at or near the binding pocket of a ligand. Hence, it is important to
utilize modified or wild-type RNA constructs in ligand screening and binding assays. The fact
that a single methylation affects the binding of a ligand is not unprecedented. Resistance to
capreomycin (a cyclic peptide antibiotic) used as an anti-tuberculosis drug can occur due to
lack of C 2'-O-methlation at 1409 of 16 S rRNA and 1920 of 23 S rRNA.324 Conversely, resistance
to kanamycin and apramycin occur due to N1-methylation of A1408 of 16 S rRNA.325 Many
antibiotic-producing bacteria protect themselves by modifying their target rRNA. Therefore, by
utilizing the typical patterns of rRNA post-transcriptional modification in different bacteria,
more specific anti-infectives can be developed to counteract the resistance problem.

ESI-MS Spectra and Binding Curves
The ESI-MS spectra and binding curves for this study are shown on the next page.
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Figure 6.5: ESI-MS data for unmodified decoding region interactions with paromomycin are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.6: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and unmodified decoding region and (D) the average of the three experiments ±
error of fit and standard deviation (in bold letters) are shown.
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Figure 6.7: ESI-MS data for modified decoding region interactions with paromomycin are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.8: Binding curves (A-C) obtained from three different ESI-MS experiments between
paromomycin and modified decoding region and (D) the average of the three experiments ±
error of fit and standard deviation (in bold letters) are shown.
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Figure 6.9: ESI-MS data for unmodified decoding region interactions with hygromycin are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.10: Binding curves (A-C) obtained from three different ESI-MS experiments between
hygromycin and unmodified decoding region and (D) the average of the three experiments ±
error of fit and standard deviation (in bold letters) are shown.
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Figure 6.11: ESI-MS data for modified decoding region interactions with hygromycin are shown.
The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.12: Binding curves (A-C) obtained from three different ESI-MS experiments between
hygromycin and modified decoding region and (D) the average of the three experiments ± error
of fit and standard deviation (in bold letters) are shown.
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Figure 6.13: ESI-MS data for unmodified decoding region interactions with DHR23 are shown.
The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.14: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and unmodified decoding region and (D) the average of the three experiments ± error of
fit and standard deviation (in bold letters) are shown.
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Figure 6.15: ESI-MS data for modified decoding region interactions with DHR23 are shown. The
experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.16: Binding curves (A-C) obtained from three different ESI-MS experiments between
DHR23 and modified decoding region and (D) the average of the three experiments ± error of fit
and standard deviation (in bold letters) are shown.
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Figure 6.17: ESI-MS data for unmodified decoding region interactions with HPVHHYQ are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.18: Binding curves (A-C) obtained from three different ESI-MS experiments between
HPVHHYQ and unmodified decoding region and (D) the average of the three experiments ±
error of fit and standard deviation (in bold letters) are shown.
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Figure 6.19: ESI-MS data for modified decoding region interactions with HPVHHYQ are shown.
The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.20: Binding curves (A-C) obtained from three different ESI-MS experiments between
HPVHHYQ and modified decoding region and (D) the average of the three experiments ± error
of fit and standard deviation (in bold letters) are shown.
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Figure 6.21: ESI-MS data for unmodified decoding region interactions with neomycin are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.22: ESI-MS data for modified decoding region interactions with neomycin are shown.
The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.23: Binding curve (A) obtained from two different ESI-MS experiments between
neomycin and unmodified decoding region and (B) the average of the two experiments ± error
of fit and standard deviation (in bold letters) are shown are shown.
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Figure 6.24: Binding curve (A) obtained from two different ESI-MS experiments between
neomycin and modified decoding region and (B) the average of the two experiments ± error of
fit and standard deviation (in bold letters) are shown are shown.
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Figure 6.25: ESI-MS data for unmodified decoding region interactions with kanamycin are
shown. The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.26: ESI-MS data for modified decoding region interactions with kanamycin are shown.
The experiments were carried out in 150 mM ammonium acetate pH 7.0.
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Figure 6.27: Binding curve (A) obtained from two different ESI-MS experiments between
kanamycin and unmodified decoding region and (B) the average of the two experiments ± error
of fit and standard deviation (in bold letters) are shown are shown.
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Figure 6.28: Binding curve (A) obtained from thw0 different ESI-MS experiments between
kanamycin and modified decoding region and (B) the average of the three experiments ± error
of fit and standard deviation (in bold letters) are shown are shown.
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CHAPTER 7
CONCLUSIONS
The prevalence of antibiotic resistance poses a huge challenge for the healthcare
industry as well as research scientists.2 Development of new antibiotics has made major strides,
especially in the field of aminoglycoside research. Some brilliant efforts from many laboratories
have helped propel the improvement of the efficacy of current aminoglycosides.214, 216, 272
However, the race is far from over; more research is needed to combat the resistance
problem.114, 205 Resistance to aminoglycosides can occur in a variety of ways; however, the most
common type is enzymatic modification of their hydroxyl and amino groups, which affects the
ability of the compounds to bind to the target RNA.114, 205
This thesis work focused on improving the efficacy of current aminoglycosides by
developing and testing new derivatives. Previous structure studies suggested that the minimal
motif for specific binding of aminoglycosides to the A site of the ribosome is neamine.6
Therefore, using a reductionist approach, a series of aminoglycoside analogues based on the
neamine core was tested. The aim was to maintain the minimal structure required for specific
binding to the A site, but avoid modification by resistance enzymes. Our methodical approach
yielded new insights to aminoglycoside-RNA interactions. The binding affinity of ring I could be
enhanced by more than 100-fold through modifications at the five functional group positions.
Through incremental changes made to the parent compound in collaboration with Dr.
Mobashery and Pei-Wen Chao, we were able to determine that charge formation or hydrogen
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bonding at the N1 position of ring I is critical for binding to the A site.201 Also, addition of a γamino-α-hydroxybutyryl group at the N1 position enhanced the binding affinity of ring I by
approximately 40-fold. In contrast, addition of a second γ-amino-α-hydroxybutyryl group at N6
decreased the binding affinity by three-fold.201 These results among others indicate that bulky
groups are not well tolerated at the N6 position.
The analogue with the best affinity to the A site (DHR23), was determined through
footprinting assays to bind to the internal bulge region of the A-site RNA. This was a very
encouraging result because, in spite of the absence of the other three rings in paromomycin,
DHR23 was still able to bind to the internal bulge region of the A-site RNA. However, the
binding of DHR23 to this region did not elicit the conformational changes similar to that
observed upon paromomycin binding.95, 207, 237 This result suggests that the other rings in
paromomycin may position it in a unique way in order to have specific contacts with the RNA,
which are absent in DHR23. The lesson learned from this result is that specific binding to the A
site is not a guarantee for antibacterial activity; however, including functionalities that can
mimic the contacts made by the other rings in paromomycin would be fruitful in generating
functionally useful A-site binders.
In the quest to develop new antibiotics, one of the major impediments is the availability
of relatively simple high-throughput methods to screen RNA-binding ligands. In our efforts to
bridge this gap, a fluorescent indicator (TO-PRO) method was developed.166 ESI-MS was
employed to investigate the mechanism of the assay, and the results obtained provide
molecular evidence that correlates the reduction in fluorescence observed in the FID assay with
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the displacement of the TO-PRO dye molecule from RNA. The assay was successfully applied to
screen a variety of RNA ligands and our results suggest that this assay is an appropriate method
for obtaining relative binding affinities of a variety of ligands to RNA, including amino sugars,
peptides, and planar aromatic compounds. The FID assay will be amenable to high-throughput
screening because it is a sensitive, fluorescence-based method that can be done on 96- or 384well plate formats. Furthermore, the system is compatible with cationic buffer components,
including Mg2+, Na+, and K+, which are not suitable for ESI-MS screening.
One reason why aminoglycosides are effective antibiotics is because they preferentially
target bacterial ribosomes over eukaryotic ribosomes.163 This is due to subtle nucleotide
differences in the A site of the bacteria as compared to eukaryotes. Binding studies were
performed to test specificity of DHR23 compared to paromomycin, and also to identify new
potential RNA targets. In the absence of the other rings in paromomycin, DHR23 had a 10-fold
decrease in affinity to the bacterial A site. Even with this reduction in affinity, it still retained a
slight preference for the bacterial A-site RNA over the human A-site RNA. This selectivity may
be an inherent property of amino sugars which makes them structurally compatible with the
bacterial A-site internal bulge. This was evident in both the FID and specificity studies in which
RNAs such as H69 and TAR RNA that fold into tertiary structure conformations similar to that of
the A-site internal bulge293, 326 provided scaffolds for favorable binding of paromomycin and
DHR23. This was contrasted with poor binding of paromomycin and DHR23 to h31, a helix that
adopts a conformation very different from the A-site internal bulge region.106

176

In the last part of this thesis work, the effect of modified nucleotides on ligand binding
was explored using ESI-MS. There are numerous modified nucleotides present in the
ribosome.46 The modified nucleotides are thought to modulate the specific folding of the RNA
in a variety of ways including improving base stacking,294-296 and increasing or decreasing the
potential for hydrogen bonding.297-299 These properties may affect RNA-ligand interactions.
Ligand-binding experiments were performed with modified and unmodified decoding region
constructs. Our results indicate that modified nucleotides may affect binding affinity if they are
present at or near the ligand-binding pocket. For example, the affinity of hygromycin B for the
modified decoding region was enhanced by approximately 1.5-fold due to the presence of the
modified nucleotide m3U1498. This increase in affinity could be due to enhanced hydrogenbond interactions between the modified nucleotide and hygromycin or due subtle
conformational changes resulting from the presence of the modified nucleotides, which lead to
favorable interactions with the RNA. Conversely, the presence of the modified nucleotide
m5C1407 appeared to decrease the affinity of peptide HPVHHYQ for the modified decoding
region construct. This result was not surprising because HPVHHYQ was selected through phage
display against an unmodified A-site RNA.314 Thus, these results suggest that as synthesis of
modified nucleosides becomes more accessible and less expensive, it would be worthwhile to
use modified nucleotides or wild-type nucleotides in ligand screening and selection assays.
In summary, the results from this work have shown that generation of compounds
based on these simplified structures in combination with FID screening may lead to selective
reagents for RNA internal bulges, loops, mismatches, or other unique secondary structure
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elements. Also, including functional groups that mimic the contacts made by rings II-IV of
paromomycin and screening with wild-type (modified) RNA constructs may lead to
identification of ligands high selectivity and efficacy.
Future plans to improve the efficacy of DHR23 include coupling it with HPVHHYQ, a
peptide found to stabilize the flipped out conformation of A1492 and A1493 (Figure 7.1).314 We
hypothesize that conjugating the two compounds will have a synergistic effect; imparting on
the hybrid compound the specificity of DHR23 and the efficacy of HPVHHYQ. Also, molecular
modeling of DHR23 bound to the A site will be helpful to determine the kinds of functionalities
that can be added to DHR23 in order to mimic the specific interactions observed between the
parent compound paromomycin and the A site. Information from the molecular modeling
studies will be valuable in generating functionally useful A-site binders. Another avenue worth
exploring is coupling DHR23 to planar molecules such as CR1119 (Chapter 4) (Figure 7.2). This
may result in generation of molecules that specifically target structured RNA including internal
loops and hairpins loops.327

Figure 7.1: Chemical structure of DHR23 conjugated to HPVHHYQ is shown
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Figure 7.2: Chemical structure of DHR23 conjugated to a truncated CR1119 is shown.
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A series of single-ring aminoglycoside analogues was tested for binding to a model RNA
representing the A site using electrospray ionization mass spectrometry (ESI-MS). Several of the
synthetic analogues with low molecular weights were found to bind to the RNA with affinities
comparable to the parental aminoglycoside neamine, with apparent dissociation constants in
the low micromolar range. Salt dependence of the affinity constants for the single-ring
analogues revealed a predominantly electrostatic binding mode. Footprinting experiments
revealed that one of the compounds (DHR23) has a similar binding site as the antibiotic
paromomycin. Dimethyl sulphate (DMS) chemical probing results also suggest that the binding
of DHR23 to the A site leads to stabilization of the stacked-in conformation of A1492 and
A1493.
To aid in the ligand-identification process, a modified fluorescence intercalator
displacement (FID) assay for screening RNA-binding ligands was established using 3-methyl-2-

222

((1-(3-(trimethylammonio)propyl)-4-quinolinylidene)methyl)benzothiazolium (TO-PRO) as the
fluorescent indicator. ESI-MS results provide direct evidence that correlates the reduction in
fluorescence intensity observed in the FID assay with displacement of the dye molecule from
RNA. The assay was successfully applied to screen a variety of RNA-binding ligands with a set of
small hairpin RNAs. Ligands that bind with moderate affinity to the chosen RNA constructs were
identified.
Furthermore, the specificity of one compound, DHR23, as well as a range of other
ligands were tested for binding to a set of RNA models, as well as the modified and unmodified
decoding-region RNA constructs. The results show that DHR23 has preferred binding to
structured RNA as compared to ssRNA, as well as a modest preference for the A-site RNA. Also,
our results indicate that modified nucleotides at or near the ligand-binding pocket may affect
binding affinity of small molecules.
In summary, the results from this work have shown that generation of compounds
based on these simplified structures in combination with FID screening may lead to selective
reagents for RNA internal bulges, loops, mismatches, or other unique secondary-structure
elements.
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